

AWARD NUMBER:

W81XWH-14-1-0238

TITLE:

Targeting Histone Abnormality in Triple-Negative Breast Cancer

PRINCIPAL INVESTIGATOR:

Nancy E. Davidson, M.D.

CONTRACTING ORGANIZATION:

University of Pittsburgh, Pittsburgh, PA 15213

REPORT DATE:

August 2015

TYPE OF REPORT:

Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

*Form Approved
OMB No. 0704-0188*

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE August 2015		2. REPORT TYPE Annual		3. DATES COVERED 1 Aug 2014 - 31 Jul 2015	
4. TITLE AND SUBTITLE Targeting Histone Abnormality in Triple-Negative Breast Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-14-1-0238	
				5c. PROGRAM ELEMENT NUMBER N/A	
6. AUTHOR(S) Nancy E. Davidson, M.D. E-Mail:davidsonne@upmc.edu				5d. PROJECT NUMBER N/A	
				5e. TASK NUMBER N/A	
				5f. WORK UNIT NUMBER N/A	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Pittsburgh Cancer Institute, 204 Craft Ave., Pittsburgh, PA 15213				8. PERFORMING ORGANIZATION REPORT NUMBER N/A	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S) N/A	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S) N/A	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES N/A					
14. ABSTRACT Like other cancers, triple negative breast cancer (TNBC) develops as a consequence of cumulative genetic and epigenetic changes. The goal of this funded proposal is to understand how changes in interaction of chromatin-remodeling enzymes contribute to TNBC development and to test novel targeted combination approaches of epigenetic drugs in restoration of aberrantly silenced tumor suppressor genes and inhibition of breast tumor growth. Our previous work suggested that TNBC had enhanced crosstalk between histone enzymes LSD1 and HDAC5 that promoted aberrant gene silencing and TNBC cell growth. Our ongoing studies demonstrated that crosstalk between LSD1 and HDAC5 may represent a novel and effective target for therapeutic target for TNBC. We further identified that sulforaphane, a natural HDAC inhibitor found in cruciferous vegetables, uniquely suppressed HDAC5 mRNA expression that facilitated LSD1 protein destabilization. Sulforaphane significantly inhibited growth in cultured breast cancer cells and MDA-MB-231 xenografts. Combined use with a novel LSD1 inhibitor, HCI-2509, significantly promoted antineoplastic efficacy of sulforaphane. Moreover, microarray screening in HDAC5-KD and LSD1-KD cells identified a unique subset of genes whose expression was co-regulated by HDAC5 and LSD1 signaling pathways. These novel findings suggest that HDAC5-LSD1 axis may represent a novel and effective therapeutic target for TNBC.					
15. SUBJECT TERMS Nothing listed					
16. SECURITY CLASSIFICATION OF:		17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 69	19a. NAME OF RESPONSIBLE PERSON USAMRMC	
a. REPORT Unclassified	b. ABSTRACT Unclassified			c. THIS PAGE Unclassified	19b. TELEPHONE NUMBER (include area code) N/A

Standard Form 298 (Rev. 8-98)
Prescribed by ANSI Std. Z39.18

Table of Contents

	<u>Page</u>
1. Introduction.....	4
2. Keywords.....	4
3. Accomplishments.....	4-9
4. Impact.....	9
5. Changes/Problems.....	9
6. Products.....	9
7. Participants & Other Collaborating Organizations.....	10-11
8. Special Reporting Requirements.....	11
9. Appendices.....	11-69

1. INTRODUCTION

Triple negative breast cancer (TNBC) is a more aggressive subtype of breast cancer and early distant recurrences are more common than with hormone receptor-positive counterparts. TNBC is not amenable to anti-estrogen therapy or to agents that target HER2. Therefore, new targeted approaches are urgently needed to improve TNBC therapy. Like other cancers, TNBC develops as a consequence of cumulative genetic and epigenetic changes. The epigenetic alterations include DNA methylation and histone tail modifications. Our early work suggests that enhanced crosstalk between histone enzymes LSD1 and HDAC5 promotes aberrant gene silencing and TNBC tumor cell growth. The goals of this funded proposal are to: (1) understand how changes in interaction of HDAC5 and LSD1 contribute to TNBC development; and (2) test if combined use of LSD1 and HDAC inhibitors is more efficacious in restoration of aberrantly silenced tumor suppressor genes and inhibiting tumor growth. This awarded project is a partnership between Dr. Yi Huang (initiating PI) and Dr. Nancy E. Davidson (partner PI). In the first funding year, the two labs have been working closely together, using multiple *in vitro* and *in vivo* models to decipher how to apply novel epigenetic agents in the most favorable combination strategy against TNBC and investigate how these epigenetic changes might contribute directly to TNBC tumorigenesis. The Davidson lab tested the *in vivo* therapeutic effect of a natural HDAC inhibitor (HDACi), sulforaphane, alone or in combination with LSD1 inhibitor HCI-2509 in MDA-MB-231 xenografts in mice. Moreover, the Davidson team collaborated with the Huang team on the analysis of basic mechanisms underlying how HDAC5 interacts with LSD1 complex and stabilizes its protein expression and activity in breast cancer. These new findings provided strong evidence to support our hypothesis that HDAC5-LSD1 axis represents a promising therapeutic target for improving HDACi efficacy in TNBC.

2. KEYWORDS

breast cancer, HDAC5, LSD1, USP28, sulforaphane, combination therapy, microarray study

3. ACCOMPLISHMENTS

a. What were the major goals of the project?

The hypothesis for our work is that silencing of key tumor suppressive genes by enhanced crosstalk between LSD1 and HDACs is a unique epigenetic mechanism promoting TNBC growth and metastasis, and blockade of the LSD1/HDAC axis results in profound inhibition of TNBC growth and metastasis, mediated at least in part via induction of RGS16. This is to be addressed through three specific aims:

- 1.** Delineate the molecular basis by which inhibition of LSD1 promotes HDACi-induced apoptosis through reactivation of aberrantly silenced tumor suppressor genes.
- 2.** Elucidate the role of LSD1 in HDACi therapy and chemoprevention of TNBC in animal models.
- 3.** Evaluate therapeutic effects of combination strategies in patient-derived xenografts (PDXs).

b. What was accomplished under these goals?

Proposed Aims	Accomplishment
Specific Aim 1: Delineate the molecular basis by which inhibition of LSD1 promotes	The Davidson team collaborated with the Huang team on the analysis of basic mechanisms underlying

HDACi-induced apoptosis through reactivation of aberrantly silenced tumor suppressor genes.	how HDAC5 interacts with LSD1 complex and stabilizes its protein expression and activity in breast cancer and how HDAC5-LSD1 axis promotes breast cancer tumorigenesis.
Major Task 1: Determine the role of LSD1/HDACs axis in promoting tumorigenic transformation of TNBC.	
Subtask 1: Submit IRB approval for use of LSD1/HDAC expression plasmids. (Month 1-2)	The proposed work was approved by University of Pittsburgh Institutional Review Board (PRO14030148, 3/10/2014).
Subtask 2: Establish MCF-10A cells with overexpression of LSD1, HDAC1, HDAC5 or combination. (Month 3-6)	These studies were carried out in Huang Lab (see Dr. Huang's report)
Subtask 3: Treat transfected MCF-10A cells for 6 months with mutagen ICR191 and test the potential transformation of transfected MCF-10A cells in 3D culture (Month 7-15).	We have provided Dr. Huang technical support in performing these experiments, e.g. breast cancer cell 3D culture on soft agar (see the results in Dr. Huang's report).
Major Task 2: Elucidate the role of RGS16 signaling pathway in LSD1-mediated HDACi efficacy in TNBC.	
Subtask 1: Stable knockdown of RGS16 expression in MCF-10A cells (Month 5-8).	The generation of stable MCF-10A-RGS16-KD cell line is still in progress.
Subtask 2: Evaluate whether silencing of RGS16 promotes MCF-10A tumorigenesis (Month 8-12).	Once the stable MCF-10A-RGS16-KD cell line is successfully generated, we will examine the effect of RGS16 inhibition on MCF-10A cell tumorigenesis.
Other reportable results: To study the correlation in protein expression of HDAC5 and LSD1 in human breast cancer.	To study the potential association of HDAC5 and LSD1 in human breast cancer, we examined mRNA levels of HDAC5 and LSD1 in human immortalized normal mammary epithelial MCF10A cells, fully malignant MCF10A-CA1a cells transformed from MCF10A cells with transfection of <i>HRAS</i> oncogene, and several human breast cancer cell lines. qPCR studies showed that there was no clear association of mRNA expression of HDAC5 and LSD1 in breast cancer cell lines (Fig. 1A). However protein expression of both HDAC5 and LSD1 was significantly elevated in all malignant breast cell lines compared with MCF10A (Fig. 1B). Quantitative immunoblotting analysis showed that protein levels of HDAC5 and LSD1 were positively correlated (Fig. 1C). The correlation of HDAC5 and LSD1 protein expression was further evaluated in 50 primary breast cancer patient specimens by immunohistochemistry (IHC) using a commercially available tissue microarray (US Biomax, Rockville, MD). Standard staining procedure for paraffin sections was used for

IHC according to manufacturer's recommendations (Vector Labs, Inc., Burlingame, CA). Monoclonal antibodies were used for detection of LSD1 (1:800; Cell Signaling, Danvers, MA) and HDAC5 (1:100; Santa Cruz). The staining was visualized using diaminobenzidine, and quantitated using IHC Profiler, an ImageJ plugin to calculate H-score. Chi-square study was used to assess the correlation between HDAC5 and LSD1 protein expression by using median H-scores as the cutoff for high vs low protein expression. The study showed a statistically significant correlation between HDAC5 and LSD1 protein expression in these tumors ($p<0.05$) (Fig. 1D). Furthermore, IHC analysis showed that breast cancer tissues ($n=18$) expressed significantly higher level of HDAC5 and LSD1 than their matched normal adjacent tissues ($n=18$) (Fig. 1E). The mean H-score for HDAC5 staining in stage 3 breast tumors ($n=25$) was statistically significantly higher than stage 2 counterparts ($n=25$). The mean H-score of LSD1 staining for stage 3 tumors was also higher than that of stage 2 tumors with a p-value of 0.07 (Fig. 1F). Taken together, these findings suggest that HDAC5 and LSD1 proteins are coordinately overexpressed in human breast cancer cell lines and tissue specimens.




Figure 1. Protein expression of HDAC5 and LSD1 is positively correlated. (A) mRNA expression of HDAC5 and LSD1 in breast cancer cell lines was compared with that of MCF10A cells as fold 1. Data are means \pm SD of three independent experiments. (B) Immunoblots with anti-HDAC5 and LSD1 in indicated cell lines. (C) Histograms represent the mean protein levels of HDAC5 or LSD1 in breast cancer cell lines versus MCF10A cells (as fold 1) in three determinations. Data are means \pm SD of three independent experiments. β -actin was used as control. (D) 50 primary human invasive breast tumor samples were immunostained with antibodies against HDAC5 or LSD1. Chi-square study was performed by using median H-scores as the cutoff for high vs low protein expression. (E) Representative HDAC5 and LSD1 staining (20x) in invasive breast carcinoma and adjacent normal tissue from one representative patient. H-scores represent average staining intensity in breast tumors ($n=18$) versus adjacent normal breast tissue ($n=18$). (F) Representative HDAC5 and LSD1 staining (20x) in stage 2 and 3 invasive breast carcinoma patients. H-scores represent average staining intensity in stage 3 breast tumors ($n=25$) versus stage 2 breast tumors ($n=25$). * $p<0.05$, ** $p<0.01$, *** $p<0.001$ (student's t-test).

Proposed Aims	Accomplishment
Specific Aim 2: Elucidate the role of LSD1 in HDACi therapy and chemoprevention of TNBC in animal models.	The Davidson lab carried out the animal experiments and orchestrated the sample collection and analysis, histological and pathological examinations of tissues, and interpretation of the results generated from <i>in vivo</i> studies. Her team also collaborated with the Huang team on the analysis of epigenetic markers in the tissues derived from these studies.
Major Task 4: Evaluate <i>in vivo</i> therapeutic effects of combination strategies using LSD1 inhibitors and HDACi in different subtypes of breast tumors.	
Subtask 1: Submit documents for local IACUC review (Month 6-8).	The research proposal has been approved by The University of Pittsburgh's Institutional Animal Care and Use Committee (Protocol #: 14033448, 3/24/2014, PI: Davidson).
Subtask 2: Examine the <i>in vivo</i> effects of LSD1/HDAC signaling on tumorigenic transformation of MCF-10A cells (Month 8-16).	We are currently evaluating the role HDAC5/LSD1 in breast tumorigenesis in cell line model, and anticipate that the study in MCF-10A xenograft-bearing mice will start soon after we complete the <i>in vitro</i> examination.
Subtask 3: Evaluate combination strategies using LSD1i and HDACi in different subtypes of breast tumors (Month 10-26).	<p>We first investigated the combinatorial effect of sulforaphane and a novel LSD1 inhibitor HCI-2509 in TNBC cells. shRNA-mediated depletion of LSD1 sensitized MDA-MB-231 cells to sulforaphane evidenced by significantly reduced IC₅₀ value (Fig. 2A), suggesting that loss of LSD1 enhances growth inhibition by sulforaphane. Next, we investigated whether combined use of HCI-2509 with sulforaphane could lead to a synergistic effect on growth inhibition. MDA-MB-231 and MDA-MB468 cells were simultaneously treated with sulforaphane and HCI-2509. By using Chou-Talalay model, strong synergistic growth inhibition between sulforaphane and HCI-2509 was observed in both cell lines (CI<1) (Fig. 2B).</p> <p>On the basis of the above findings, we further tested the <i>in vivo</i> therapeutic effect of sulforaphane alone or in combination with HCI-2509 using MDA-MB-231 xenografts in athymic nude mice. BALB/c nu/nu athymic nude mice (Harlan Bioproducts, Indianapolis, IN) were implanted at fat pad with 3×10⁶ MDA-MB-231 cells. When average tumor size was > 50 mm³ (Tumor volume</p>

= width × width × length/2), mice were randomized into control and treatment groups with the following doses: Vehicle (DMSO, n=12), sulforaphane treatment (50 mg/kg, n= 12), HCl-2509 (30mg/kg, n = 13), combination treatment (sulforaphane 50mg/kg, HCl-2509mg/kg, n=14). The drugs were administered by intraperitoneal (i.p.) injection 5 days/week for 4 weeks. Tumor volumes and body weights were measured every three days following the initial treatment and continued throughout the course of the study. Treatment with either sulforaphane or HCl-2509 alone significantly inhibited growth of MDA-MB-231 xenografts. Combined treatment with both compounds exhibited statistically significantly greater inhibitory effect on tumor growth than either therapy alone (**Fig. 3A & 3B**). During the course of treatment, there was no obvious weight loss observed in groups treated with sulforaphane or HCl-2509 alone, except a moderate decrease of weight (<10% of body weight) in the group treated with both compounds. No animals died from treatment (**Fig. 3C**). These results indicate that sulforaphane effectively inhibits growth of TNBC tumor *in vivo* and is more effective when used in combination with an LSD1 inhibitor.





Figure 2. LSD1 inhibitor sensitizes breast cancer cells to sulforaphane-induced growth inhibition. (A) Scramble or LSD1-shRNA transfected MDA-MB-231 cells were treated with 25 μ M sulforaphane followed by crystal violet assays. (B) Effect of combination therapy on growth. Synergy was defined as any CI < 1. Data are means \pm SD of three independent experiments. ** p<0.01, student's t-test.




Figure 3. LSD1 inhibitor sensitizes breast cancer cells to sulforaphane-induced growth inhibition. (A) Tumor volumes of mice measured twice weekly. The vertical bars indicate mean tumor size (in mm³) \pm SE. (B) Weight of animal tumors was measured at the end of experiment. (C) Weights of mice were measured in the indicated days. The vertical bars represent mean mouse weight \pm SE** p<0.01, *** p<0.001 (student's t-test).

c. What opportunities for training and professional development has the project provided?

This award provides an excellent vehicle for a postdoctoral fellow, Chunyu Cao, PhD, who has worked on this project to advance his breast cancer research career and transition to independence.

d. How were the results disseminated to communities of interest?

The progress of this work was presented by Dr. Cao at the 2015 annual meeting of American Association of Cancer Research (AACR): Cao C, Vasilatos S, Oesterreich S, Davidson NE, Huang Y. Functional crosstalk between histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) as a novel therapeutic target in triple-negative breast cancer cells. The 106th AACR Annual Meeting, Philadelphia PA, Cancer Res, Abstract 3838, 2015.

This work was also presented by Dr. Cao at 27th Annual University of Pittsburgh Cancer Institute Scientific Retreat in June, 2015 as well as the Women's Cancer Research Center Annual retreat at the University of Pittsburgh in October, 2015.

One manuscript has been submitted to *Oncogene* for publication and it is currently under revision.

What do you plan to do during the next reporting period to accomplish the goals?

During the next reporting period we will continue to elucidate how sulforaphane suppresses HDAC5-LSD1 signaling and alters chromatin structures in TNBC. We will clarify the mechanism of sulforaphane-induced downregulation of HDAC5 transcription, and examine how sulforaphane inhibit LSD1-USP28 interaction through downregulation of HDAC5 expression. Finally we will acquire or generate HDAC5 transgenic/knockout mouse models to validate our hypothesis that HDAC5-LSD1 axis represents a promising therapeutic target for TNBC.

4. IMPACT

(a) What was the impact on the development of the principal discipline(s) of the project?

TNBC comprises those breast cancers that lack expression of estrogen receptor (ER), progesterone receptor (PR), and HER-2 protein. Clinically, TNBC is more aggressive and distant recurrences in visceral organs are more common in TNBC patients than their hormone receptor-positive counterparts. Our studies have opened a new avenue for the potential utility of crosstalk between HDAC5 and LSD1 as a new therapeutic target in TNBC. Our work addresses an important research area that has been understudied in invasive breast cancer. As epigenetic therapies are currently being clinically tested, our new strategy using a natural HDAC inhibitor and a novel LSD1 inhibitor has great potential to be rapidly translated into clinical trials. The information derived from our newly completed microarray study reported in the Huang progress report will likely identify a new panel of aberrantly silenced tumor suppressor genes targeted by HDAC5/LSD1 axis that has the potential to serve as a novel panel of biomarkers to predict response or resistance to epigenetic therapy in TNBC patients.

(b) What was the impact on other disciplines? Nothing to Report

(c) What was the impact on technology transfer? Nothing to Report

5. CHANGES/PROBLEMS

(a) Changes in approach and reasons for change

No major changes in approach have been made since the initiation of the award.

(b) Actual or anticipated problems or delays and actions or plans to resolve them

Nothing to Report

(c) Changes that had a significant impact on expenditures

Nothing to Report

(d) Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

The natural HDAC inhibitor sulforaphane and novel LSD1 inhibitor HCI-2509 have been added as new agents to study their ability in targeting HDAC5-LSD1 axis in breast cancer. We will obtain approval to extend our findings to human tissues.

6. PRODUCTS

(a) Publications, conference papers, and presentations

Cao C, Vasilatos S, Oesterreich S, Davidson NE, Huang Y. Functional crosstalk between histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) as a novel therapeutic target in triple-negative breast cancer cells. The 106th AACR Annual Meeting, Philadelphia PA, Cancer Res, Abstract#: 3838, 2015.

(b) Website(s) or other Internet site(s) Nothing to Report

(c) Technologies or techniques Nothing to Report

(d) Inventions, patent applications, and/or licenses Nothing to Report

(e) Other Products Nothing to Report

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

a) Individuals have worked on the project

Name:	Nancy Davidson	Yi Huang	Chunyu Cao	Shauna Vasilatos
Project Role:	Co-PI	Co-PI	Postdoc Fellow	Technician
Researcher Identifier (e.g. ORCID ID):	N/A	N/A	N/A	N/A
Nearest person month worked:	1.2	3.6	6.0	9.0

Contribution to Project:	Oversaw IHC studies and animal experiments, and interpreted the results generated from <i>in vivo</i> studies	Designed and oversaw the studies to define in depth the basic mechanisms and biological consequences of the functional interplay between HDAC5/LSD1 in breast cancer	Studied molecular mechanisms by which LSD1 and HDAC interacted, and carried out animal study	Performed IHC and microarray studies, oversaw critical lab management activities
Funding Support:	CDMRP Breast Cancer Breakthrough Award and Breast Cancer Research Foundation	CDMRP Breast Cancer Breakthrough Award and Breast Cancer Research Foundation	CDMRP Breast Cancer Breakthrough Award	CDMRP Breast Cancer Breakthrough Award

b) Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Dr. Tiffany Katz completed her postdoctoral fellow training, and Dr. Chunyu Cao joined the laboratory carry out the studies.

c) What other organizations were involved as partners?

Nothing to Report

8. SPECIAL REPORTING REQUIREMENTS

COLLABORATIVE AWARDS: Initiating PI, Dr. Yi Huang, will submit his annual report separately.

QUAD CHARTS: N/A

9. APPENDICES:

updated curriculum vitae is attached

CURRICULUM VITAE
University of Pittsburgh
School of Medicine

BIOGRAPHICAL

Name: Nancy Ellen Davidson, MD

Business Address:

University of Pittsburgh Cancer Institute
University of Pittsburgh
UPMC Cancer Pavilion
5150 Centre Avenue, Suite 500
Pittsburgh, PA 15232

EDUCATION and TRAINING

UNDERGRADUATE:

1975 BA, Wellesley College, Wellesley, Massachusetts

GRADUATE:

1979 Harvard Medical School, Boston, Massachusetts

POSTGRADUATE:

1979-1980 Intern, Internal Medicine, Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
1980-1982 Resident, Internal Medicine, The Johns Hopkins Hospital
Baltimore, Maryland
1982-1985 Medical Staff Fellow, National Cancer Institute,
National Institutes of Health, Bethesda, Maryland

APPOINTMENTS and POSITIONS***ACADEMIC: (Institutional)***

1985-1987	Guest Worker Medical Breast Cancer Section, Medicine Branch, National Cancer Institute Bethesda, Maryland
1985-1986	Research Assistant Professor of Pharmacology Uniformed Services University of Health Sciences Bethesda, Maryland
1986-1992	Assistant Professor of Oncology The Johns Hopkins University School of Medicine Baltimore, Maryland
1992-1999	Associate Professor of Oncology The Johns Hopkins University School of Medicine Baltimore, Maryland
1995-2009	Breast Cancer Research Chair of Oncology, The Johns Hopkins University School of Medicine Baltimore, Maryland
1999-2009	Professor of Oncology The Johns Hopkins University School of Medicine Baltimore, Maryland
1986-2009	Active Staff, Johns Hopkins Hospital Baltimore, Maryland
1994-2009	Director, Breast Cancer Program The Johns Hopkins Oncology Center Baltimore, Maryland
1997-2009	Joint Appointment in Department of Biochemistry and Molecular Biology The Johns Hopkins Bloomberg School of Public Health
2009-	Adjunct Professor of Oncology, The Johns Hopkins University School of Medicine Baltimore, Maryland
2009-2010	Chief, Division of Hematology/Oncology University of Pittsburgh School of Medicine Pittsburgh, PA
2009-	Director, University of Pittsburgh Cancer Institute and UPMC CancerCenter Professor of Medicine and Pharmacology and Chemical Biology Associate Vice Chancellor for Cancer Research Hillman Professor of Oncology University of Pittsburgh, PA
2010-	Professor, Clinical and Translational Science Institute
2013-	Distinguished Professor of Medicine

CERTIFICATION AND LICENSURE

SPECIALTY CERTIFICATION:

<i>Certifying Board</i>	<i>Year</i>
National Board of Medical Examiners	1980
American Board of Internal Medicine	1982
Medical Oncology	1985
<i>Medical or other Professional Licensure:</i>	
State of Maryland	1982
Commonwealth of Pennsylvania	2009

MEMBERSHIPS IN PROFESSIONAL SCIENTIFIC SOCIETIES

SOCIETIES

1985-present	American Society of Clinical Oncology
1992, 1998, 2002-3	Member, Program Committee
1992, 1993, 1998	Session Chairman
1992-1996	Member, Public Issues Committee
1992-1996	Member, Award Selection Committee
1994-1995	Chair, Award Selection Committee
1993-1994	Member, Ad hoc Technology Assessment Committee for Development of Growth Factor Clinical Practice Guidelines
1996- present	Co-Chair, Breast Cancer Follow-up Testing Guidelines Expert Panel
1997-1999	Member, Membership Committee
1996-1999	Member, Board of Directors
1999-2002	Member, Grants Selection Committee
1999-2004	Member, Task Force on Quality of Cancer Care
2004-2007	Member, Publications Committee
2005-2006	Chair, Publications Committee
2005-2006	Member, Translational Research Task Force
2006-2009	President-Elect, President, and Immediate Past President
2007-present	Member, Value in Cancer Care Task Force
2008-2009	Chair, Special Awards Selection Committee
2008-2009	Member, Translational Research Professorship Selection Committee
2013-2015	Government Relations Committee
2010-2014	By-laws Committee, Chair 2012-14
1988- present	American Association for Cancer Research
1991, 1995, 1998,	Session Chair
2004, 2006, 2013	
1993-1997	Member, Maryland Legislative Committee

2000-2001, 2002-2003	Member, Program Committee
2003-2004	Co-Chair, Program Committee
2001	Member, Clinical Cancer Research Committee
1998-1999, 2001-2003	Member, AACR-Richard and Hinda Rosenthal Foundation Award Selection Committee
2002-2005	Member, Board of Directors
2003-2004	Chair, Education Committee
2004-2005	Member, Grants Selection Committee
2004-2005	Member, Lifetime Achievement Award Selection Committee
2005-2006	Member, Landon Award Selection Committee
2008-2009	Chair, AACR-Breast Cancer Research Foundation Grants Selection Committee
2008-2009	Member, Landon Translational Award Selection Committee
2008	Co-Chair, Program Committee, 7 th Annual Frontiers in Cancer Prevention Research Conference
2010-2012	Member and Chair (2010-11), AACR Nominating Committee
2010-present	Member, Continuing Medical Education Committee, (Chair 2015-)
2012-2013	Member, Education Committee
2011-2014	Member, Program Committee, AACR-San Antonio Breast Cancer Symposium
2015-2018	President-Elect, President, and Immediate Past President

1987-present

1987-present	Member, Breast Cancer Core Committee
1992-1996	Chair, Breast Cancer Biology Committee
1992-1996	Co-Chair, Breast Cancer Committee
1997-2002	Chair - Breast Cancer Committee

2009-present

American College of Physicians

Member	
Member, National Surgical Adjuvant Bowel and Breast Project	
Member, Board of Directors, Association of American Cancer Institutes	
Member, Association of American Physicians Council	

HONORS

1974	Phi Beta Kappa
1975	Sigma X
1986-1987	American Society of Clinical Oncology Young Investigator Award
1987-1988	Susan Komen Foundation Award
1988-1991	American Cancer Society Clinical Oncology Career Development Award
1989-1990	Merck Clinician Scientist Award
1995-2009	Breast Cancer Research Chair in Oncology, Johns Hopkins

1998	ACS Research Award, American Cancer Society - Maryland Division
1999	Brinker International Award for Breast Cancer Research
2000	Wellesley College Alumnae Achievement Award
2001	William L. McGuire Memorial Lectureship, 24 th Annual San Antonio Breast Cancer Symposium
2003	Avon Foundation Medical Advancement Award
2007-8	President, American Society of Clinical Oncology
2008	7 th Rosalind E. Franklin Award for Women in Science, National Cancer Institute
2008	11 th American Association for Cancer Research-Women in Cancer Research Charlotte Friend Award
2009	Johns Hopkins University Alumni Association Distinguished Alumna Award
2010	American Society of Clinical Oncology Gianni Bonadonna Breast Cancer Award
2010	Association of American Physicians
2011	National Academy of Medicine (formerly the Institute of Medicine)
2012	Pennsylvania Breast Cancer Coalition Potamkin Award
2013	Distinguished Professor of Medicine, University of Pittsburgh.
2014	Thomson Reuters Highly Cited Researchers 2014
2015	The Johns Hopkins Women's Medical Alumnae Association Hall of Fame
2016	Fellow, American College of Physicians

Publications

Articles Published in Professional Journals

1. Kensler TW, Busby WF, Jr., Davidson NE, and Wogan GN. Aflatoxin inhibition of glucocorticoid binding capacity of rat liver nuclei. *Biochim. Biophys. Acta* 473:200-10, 1976. PMID 181075
2. Kensler TW, Busby WF, Davidson NE, and Wogan GN. Effect of hepatocarcinogens on the binding of glucocorticoid-receptor complex in rat liver nuclei. *Cancer Res.* 36:4647-51, 1976. PMID 1000507
3. Michejda CJ, Davidson NE, and Keefer LK. Photochemical perturbation of Z=E equilibria in nitrosamines. *J. Chemistry Soc. Chem. Comm.* 633-634, 1976
4. Hochberg MC, Davidson NE, and Kim WS. Lupus nephritis. *Johns Hopkins Med. J.* 150:101-106, 1982. PMID 7062572
5. Davidson NE, Bronzert DA, Chambon P, Gelmann EP and Lippman ME. Use of two MCF-7 cell variants to evaluate the growth regulatory potential of estrogen-induced products. *Cancer Res.* 46:1904-08, 1986. PMID 3948173
6. Kasid A, Davidson NE, Gelmann EP and Lippman ME. Transcriptional control of thymidine kinase gene expression by estrogens and antiestrogens in MCF-7 human breast cancer cells. *J. Biol. Chem.* 261:5562-7, 1986. PMID 2420802
7. Lippman ME, Dickson R, Kasid A, Gelmann EP, Davidson NE, McManaway M, Huff K, Bronzert D, Bates S, Swain S and Knabbe C. Autocrine and paracrine growth regulation of human breast cancer. *J. Steroid Biochem.* 24:147-54, 1986. PMID 3486321

8. Bronzert DA, Davidson N, and Lippman M. Estrogen and antiestrogen resistance in human breast cancer cell lines. *Adv. Exp. Med. Biol.* 196:329-45, 1986. PMID 3521223
9. Kensler TW, Egner PA, Davidson NE, Roebuck BD, Pikul A, and Groopman JD. Modulation of aflatoxin metabolism, aflatoxin- N7-quanine formation, and hepatic tumorigenesis in rats fed ethoxyquin: role of induction of glutathione S-transferases. *Cancer Res.*, 46:3924-31, 1986. PMID 2873884
10. Davidson NE, Gelmann EP, Lippman ME and Dickson RB. EGF receptor gene expression in estrogen receptor positive and negative human breast cancer cell lines. *Molecular Endocrinology* 1:216-23, 1987. PMID 3502607
11. Lippman ME, Bates S, Huff KK, Davidson N and Dickson R. Estrogens regulate production of specific growth factors in hormone- dependent human breast cancer. *J. Lab. Clin. Med.* 109:230-5, 1987. PMID 3469292
12. Bronzert DA, Pantazis P, Antoniades HN, Kasid A, Davidson NE, Dickson RB, and Lippman ME. Synthesis and secretion of PDGF-like growth factor by human breast cancer cell lines. *Proc. Natl. Acad. Sci. USA* 84:5763-7, 1987. PMC298943
13. Bates SB and Davidson NE, Valverius EM, Dickson RB, Freter CE, Tam JP, Kudlow JE, Lippman ME and Salomon D. Expression of transforming growth factor alpha and its mRNA in human breast cancer: its regulation by estrogen and its possible functional significance. *Molecular Endocrinology* 2:543-55, 1988. PMID: 3047555
14. Davidson NE and Lippman ME. The role of estrogens in growth regulation of breast cancer. *Crit. Rev. Oncogenesis* 1:89-111, 1989. PMID 2488125
15. Geller RB, Boone LB, Karp JE, Davidson N, Selonick SE, Edwards J and Burke PJ. Secondary acute myelocytic leukemia after adjuvant therapy for early-stage breast carcinoma. A new complication of cyclophosphamide, methotrexate, and 5-fluorouracil therapy. *Cancer* 64:629-34, 1989. PMID 2743258
16. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC and Vogelstein B. p53 gene mutations occur in diverse human tumor types. *Nature*, 342:705-08, 1989. PMID 2531845
17. Davidson NE. Biology of breast cancer and its clinical implications. *Current Opinion in Oncology*, 1:269-76, 1989. PMID 2562285
18. Falco JP, Baylin SB, Lupu R, Borges M, Nelkin BD, Jasti R, Davidson NE, and Mabry M. v-ras induces non-small cell phenotype, with associated growth factors and receptors, in a small cell lung cancer cell line. *J Clin Inves*, 85:1740-05, 1990. PMC296635
19. Davidson NE, Egner PA and Kensler TW. Transcriptional control of glutathione S-transferase gene expression by the chemoprotective agent 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione [Oltipraz] in rat liver. *Cancer Res*, 50:2251-5, 1990. PMID 2317812
20. Abeloff MD, Beveridge R, Donehower R, Fetting J, Davidson NE, Gordon G, Waterfield W and Damron D. Sixteen week dose-intense chemotherapy in adjuvant treatment of breast cancer. *J Natl Cancer Inst*, 82:570-4, 1990. PMID 2313733
21. Davidson NE. Biology and prognostic factors of breast cancer. *Current Opinion in Oncology*, 2:1025-30, 1990. PMID 1983088

22. Rowley SD, Piantadosi S, Marcellus DC, Jones RJ, Davidson NE, Davis JM, Kennedy J, Wiley JM, Wingard J, Yeager AM and Santos GW. Analysis of factors predicting speed of hematologic recovery after transplantation with 4 hydroperoxycyclophosphamide-purged autologous bone marrow grafts. *Bone Marrow Trans.*, 7:183-91, 1991. PMID 2059755
23. Kyprianou N, English HF, Davidson NE and Isaacs JT. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. *Cancer Res.*, 51:162-6, 1991. PMID 1899037
24. Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD and Davidson NE. High dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. *J. Natl. Cancer Inst.*, 83:920-6, 1991. PMID 1906111
25. Davidson NE. Biology of breast cancer. *Current Opinion in Oncology*, 3:988-94, 1991. PMID 1843117
26. Davidson NE. and Abeloff MD. Adjuvant systemic therapy for women with high risk early breast cancer. *J. Natl. Cancer Inst.*, 84:301-5, 1992. PMID 1531367
27. Kennedy MJ, Prestigiacomo LJ, Tyler G, May WS. and Davidson NE. Differential effects of bryostatin 1 and phorbol ester on growth of human breast cancer cell lines. *Cancer Res.* 52:1278, 1992. PMID 1737390
28. Armstrong DK, Gordon GB, Hilton J, Streeper RT, Colvin OM, and Davidson, NE. Hepsulfam sensitivity in human breast cancer cell lines: the role of glutathione and glutathione-S transferase in resistance. *Cancer Res.* 52:1416-21, 1992. PMID 1540950
29. Armstrong DK, Isaacs JT, Ottaviano YL and Davidson NE. Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468. *Cancer Res.*, 52:3418-24, 1992. PMID 1534511
30. Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Shelton B, Prestigiacomo L, Vogelstein B, and Davidson N. Inherited p53 gene mutations in breast cancer. *Cancer Res.*, 52:2984-6, 1992. PMID 1581912
31. Davidson NE. Biology of breast cancer and its clinical implications. *Current Opinion in Oncology*, 4:1003-9, 1992. PMID 1457515
32. Armstrong DK, Fetting JH, Davidson NE, Gordon GB, Huelskamp AM and Abeloff, MD. Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer. *Breast Cancer Res. Treat.*, 28:277-84, 1993. PMID 8018956
33. Davidson NE, Prestigiacomo LJ and Hahn HA. Induction of jun gene family members by transforming growth factor alpha but not 17 beta-estradiol in human breast cancer cell lines. *Cancer Res.* 53:291-7, 1993. PMID 847822
34. Davidson NE, Mank AR, Prestigiacomo LJ, Bergeron RJ and Casero RA. Growth inhibition of hormone-responsive and -resistant human breast cancer cell lines by N¹,N¹²-bis(ethyl) spermine. *Cancer Res.* 53:2071-5, 1993. PMID 8481909
35. Kennedy MJ, Vogelsang GB, Beveridge RA, Farmer ER, Altomonte V, Huelskamp AM and Davidson NE. Phase I trial of intravenous cyclosporine A to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. *J Clin Oncol* 11:478-84, 1993. PMID 8445424

36. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE and Poirier GG. Specific proteolytic cleavage of poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. *Cancer Res.* 53:3976-85, 1993. PMID 8358726
37. Davidson NE and Abeloff MD. Menstrual effects on surgical treatment for breast cancer, *Cancer Treat Rev.* 19:105-12, 1993. PMID 8481925.
38. Tokino T, Davidson N, Helzlsouer K, Zehnbauer B, Nakamura Y, Vogelstein B, and Sidransky, D. Absence of germline prohibitin mutations in early onset breast cancer. *Int. J. Oncology.* 3:769-72, 1993. PMID 21573431
39. Kennedy MJ, Davis J, Passos-Coehlo J, Noga SJ, Huelskamp AM, Ohly K and Davidson NE. Administration of human recombinant granulocyte-colony stimulating factor (Filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer, *Cancer Res.* 53:5424-8, 1993. PMID 7693341
40. Ross AA, Cooper BW, Lazarus HM, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE, Sweet D, Winter C, Alcard L, Jansen J, Copelan E, Meagher RC, Herzig RH, Klumpp TR, Kahn DG and Warner NE. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques, *Blood*, 82:2605-10, 1993. PMID 8219214
41. Kronthal AJ, Fishman EK, Gottlieb LM and Davidson NE. CT evaluation of breast cancer: spectrum of disease. *Critical Reviews in Diagnostic Imaging*, 34:159-237, 1993. PMID 8216816
42. Kennedy MJ, Vogelsang GB, Jones RJ, Farmer ER, Altomonte V, Huelskamp AM, Hess A, and Davidson NE. Phase I trial of interferon-gamma to potentiate cyclosporine A-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer, *J. Clin. Oncol.* 12:249-57, 1994. PMID 8113833
43. Davidson NE. Ovarian ablation as treatment for young women with breast cancer. *J. Natl. Cancer Inst.* 16:95-9, 1994. PMID 7528032
44. Davidson NE and Abeloff MD. Adjuvant therapy of breast cancer. *World J Surg.* 18:112-6, 1994. PMID 8197765
45. Passos-Coehlo J, Ross AA, Davis JM, Huelskamp A-M, Clarke B, Noga JS, Davidson NE and Kennedy MJ. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer - effect of ex vivo purging with 4-hydroperoxycyclophosphamide. *Cancer Res.* 54:2366-71, 1994. PMID 8162582
46. Ottaviano YL, Issa J-P, Parl FF, Smith HS, Baylin SB and Davidson NE. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. *Cancer Res.* 54:2552-5, 1994. PMID 8168078
47. Issa J-P I, Ottaviano YL, Celano P, Hamilton SR, Davidson NE and Baylin SB. Methylation of the oestrogen receptor gene CpG island links ageing and neoplasia in human colon. *Nature Genetics.* 7:536-40, 1994. PMID 7951326
48. Cobleigh MA, Berris RF, Bush T, Davidson NE, Robert NJ, Sparano JA, Tormey DC and Wood WC. Estrogen replacement therapy in breast cancer survivors - a time for change. *JAMA*, 272:540-5, 1994. PMID 8046809

49. Armstrong DK, Kaufmann SH, Ottaviano YL, Furuya Y, Buckley JA, Isaacs JT and Davidson NE. Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. *Cancer Res.* 54:5280-3, 1994. PMID 7923154
50. May WS, Tyler PG, Ito T, Armstrong DK, Qatsha KA and Davidson NE. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 in association with suppression of apoptosis. *J. Biol. Chem.* 269:26865-70, 1994. PMID 7929424
51. ASCO Ad Hoc Colony-Stimulating Factor Guideline Expert Panel, American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. *J. Clin. Oncol.* 12:2471-2508, 1994. PMID 7964965
52. Passos-Coehlo JL, Ross AA, Moss TJ, Davis JM, Huelskamp A-M, Noga SJ Davidson NE and Kennedy MJ. Absence of breast cancer cells in a single day peripheral blood progenitor cell (PBPC) collection following priming with cyclophosphamide and granulocyte-macrophage colony-stimulating factor (GM-CSF). *Blood*, 85:1138-43, 1995. PMID 7849302.
53. Passos-Coehlo JL, Braine HG, Davis JM, Huelskamp A-M, Schapers KG, Ohly K, Clarke B, Wright SK, Noga JS, Davidson NE and Kennedy MJ. Predictive factors for peripheral blood progenitor cell (PBPC) collection using a single large volume leukopheresis after cyclophosphamide and granulocyte-macrophage colony stimulating factor (GM-CSF) mobilization. *J. Clin. Oncol.*, 13:705-14, 1995. PMID 7533827
54. Kennedy MJ, Armstrong DK, Huelskamp AM, Ohly K, Clark BV, Colvin OM, Grochow LB, Chen T-L and Davidson NE. Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. *J. Clin. Oncol.* 13:1136-43, 1995. PMID 7738619
55. Ferguson AT, Lapidus RG, Baylin SB, and Davidson NE. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. *Cancer Res.* 55:2279-83, 1995. PMID 7538900
56. Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, Osborne CK, Davidson NE, Robert N, Tormey DC and Allred DC. Accumulation of p53 protein as a possible predictor of response to adjuvant CMFP for breast cancer. *J. Natl. Cancer Inst.* 87:1254-6, 1995. PMID 7563172.
57. McCloskey DM, Casero, Jr. RA, Woster PM and Davidson NE. Induction of programmed cell death in human breast cancer cells by an unsymmetrically alkylated polyamine analogue. *Cancer Res.* 55:3233-6, 1995. PMID 7614453
58. Herman JG, Merlo A, Mao L, Lapidus RG, Issa J-P J, Davidson NE, Sidransky D and Baylin SB. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. *Cancer Res.* 55:4525-30, 1995. PMID 7553621
59. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE and Baylin SB. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. *Cancer Res.* 55:5195-9, 1995. PMID 7585573

60. McCloskey DM, Yang J, Woster PM, Davidson NE and Casero, Jr. RA. Polyamine analog induction of programmed cell death in human lung tumor cells. *Clinical Cancer Res.* 2:441-46, 1996. PMID 4816189
61. Issa J-P, Zehnbauer BA, Civin CI, Collector M, Sharkis SJ, Davidson NE, Kaufmann SH and Baylin SB. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. *Cancer Res.* 56:973-77, 1996. PMID 8640788
62. Lapidus RG, Ferguson AT, Ottaviano YL, Parl FF, Smith HS, Weitzman SA, Baylin SB, Issa J-P and Davidson NE. Methylation of estrogen and progesterone receptor genes 5' CpG islands correlates with lack of ER and PR expression in breast tumors. *Clinical Cancer Res.* 2:805-10, 1996. PMID 9816234
63. McCloskey DE, Kaufmann SH, Prestigiacomo LJ and Davidson NE. Paclitaxel induces programmed cell death in MDA-MB-468 human breast cancer cells. *Clinical Cancer Res.* 2:847-54, 1996. PMID 9816240
64. Pizer ES, Jackisch C, Wood FW, Pasternack GR, Davidson NE and Kuhajda FP. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. *Cancer Res.* 56:2745-7, 1996. PMID 8665507
65. Passos-Coelho JL, Ross AA, Kahn DJ, Moss TJ, Davis JM, Huelskamp AM, Noga SJ, Davidson NE and Kennedy MJ. Similar breast cancer cell contamination of single-day peripheral blood progenitor cell (PBPC) collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factors. *J. Clin. Oncol.* 14:2569-75, 1996. PMID 8823337
66. Ross AA, Layton TJ, Ostrander AB, Passos-Coelho JL, Davis JM, Huelskamp AM, Noga SJ, Davidson NE, Kennedy MJ, Cooper BW, Gerson SL, Lazarus HM, Holland K, Gluck S, Moss TJ, Kaubish A, Vahdat L and Antman K. Comparative analysis of breast cancer contamination in mobilized and nonmobilized hematopoietic grafts. *J. Hematotherapy* 5:549-52, 1996. PMID 8938527
67. Jacobson LP, Zhang B-C, Zhu Y-R, Wang J-B, Wu Y, Zhang Q-N, Yu L-Y, Qian G-S, Kuang S-Y, Li Y-F, Fang X, Zarba A, Chen B, Enger C, Davidson NE, Gorman MB, Gordon GB, Prochaska HJ, Enger PA, Groopman JD, Muñoz A, Helzlsouer KJ and Kensler TW. Olitipraz chemoprevention trial in Qidong, People's Republic of China: Study design and clinical outcomes. *Cancer Epidemiol. Biomarkers Prev.* 6:257-65, 1997. PMID 9107431
68. ASCO Breast Cancer Surveillance Expert Panel (Schapira DV and Davidson, NE, co-chairs), Recommended breast cancer surveillance guidelines, *J. Clin. Oncol.* 15:2149-2156, 1997. PMID 9164230
69. Ferguson AT, Vertino PM, Spitzner JR, Baylin SB, Muller MT and Davidson NE. Role of estrogen receptor gene demethylation and DNA methyltransferase-DNA adduct formation in 5-aza-2'-deoxycytidine-induced cytotoxicity in human breast cancer cells. *J. Biol. Chem.* 272:32260-6, 1997. PMID 9405430
70. Dees EC and Davidson NE. Management of early stage breast cancer: interventions and their effectiveness. *Dis. Management Health Outcomes*, 2:270-280, 1997.
71. Ferguson AT and Davidson NE. Regulation of estrogen receptor α function in breast cancer. *Crit. Rev. Oncogenesis*. 8:29-46, 1997. PMID 9516085

72. Zhang B-C, Zhu Y-R, Wang J-B, Zhang Q-N, Qian G-S, Kuang S-Y, Li Y-F, Fang X, Yu L-Y, DeFlora S, Jacobson LP, Zarba A, Egner PA, He X, Wang J-S, Chen B, Enger CL, Davidson NE, Gordon GB, Gorman MB, Prochaska HJ, Groopman JD, Muñoz A, Helzlsouer KJ and Kensler TW. Oltipraz chemoprevention trial in Qidong, Jiangsu Province, People's Republic of China. *J. Cell. Biochem., Suppl* 28/29:166-173, 1997. PMID 9589363
73. Kensler TW, He X, Otieno M, Egner PA, Jacobson LP, Chen B, Wang J-S, Zhu Y-R, Zhang B-C, Wang J-B, Wu Y, Zhang Q-N, Qian GS, Kuang S-Y, Fang X, Li Y-F, Yu L-Y, Prochaska HJ, Davidson NE, Gordon GB, Gorman MB, Zarba A, Enger C, Muñoz A, Helzlsouer KJ, and Groopman JD. Oltipraz chemoprevention trial in Qidong, People's Republic of China: Modulation of serum aflatoxin albumin adduct biomarkers. *Cancer Epidemiol Biomarkers Prev.* 7:127-134, 1998. PMID 9488587
74. Lapidus RG, Nass SJ and Davidson NE. The loss of estrogen and progesterone receptor gene expression in human breast cancer. *J. Mammary Gland Biol. Neoplasia.* 3:85-94, 1998. PMID 10819507
75. Ferguson AT, Lapidus RG and Davidson NE. Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression. *Oncogene.* 17:577-83, 1998. PMID 9704923
76. Lapidus RG, Nass SJ, Butash KA, Parl FF, Weitzman SA, Graff JG, Herman JG and Davidson NE. Mapping of ER gene CpG island methylation by methylation specific PCR. *Cancer Res.* 58:2515-9, 1998. PMID 9635570
77. Davidson NE. Environmental estrogens and breast cancer risk. *Current Opinion in Oncology.* 10:475-478, 1998. PMID 9800120
78. Hahm HA and Davidson NE. Apoptosis in the mammary gland and breast cancer. *Endocrine-Related Cancer.* 5:199-211, 1998.
79. Hahm HA, Davidson NE, Giguere JK, DiBernardo C and O'Reilly S. Breast cancer metastatic to the choroid. *J. Clin. Oncol.* 16:2280-2, 1998. PMID 9626232
80. Davidson NE, Hahm HA, McCloskey DE, Woster PM and Casero, Jr. RA. Clinical aspects of cell death in breast cancer: the polyamine pathway as a new target for treatment. *Endocrine-Related Cancer* 6:69-73, 1999. PMID 10732790
81. Mikhak B, Zahvrak M, Abeloff M, Fetting JH, Davidson NE, Donehower R, Waterfield W and Kennedy MJ. Long-term follow-up of women treated with 16-week dose intense adjuvant chemotherapy for high risk breast cancer. *Cancer.* 85:899-904, 1999. PMID 10091768
82. Subramanyan S, Abeloff MD, Bond SE, Davidson NE, Fetting JH and Kennedy MJ. A phase I study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer. *Cancer Chemother Pharmacol.* 43:497-502, 1999. PMID 10321510
83. Kottke T, Blajeski AL, Martins M, Mesner, Jr. PW, Davidson NE, Earnshaw WC Armstrong DK and Kaufmann SH. Comparison of paclitaxel, 5-fluoro-2-deoxyuridine-, and epidermal growth factor-induced apoptosis: evidence for EGF-induced anoikis. *J. Biol. Chem.* 274:15927-15936. 1999. PMID 10336499.

84. Recht A, Gray R, Davidson NE, Fowble BL, Solin LJ, Cummings FJ, Falkson G, Falkson HC, Taylor, IV SG and Tormey DC. Local-regional failure ten years following mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. *J. Clin. Oncol.* 17:1689-1700, 1999. PMID 10561205
85. Smith TJ, Davidson NE, Schapira DV, et al. American Society of Clinical Oncology 1998 Update of recommended breast cancer surveillance guidelines. *J. Clin. Oncol.* 17:1080-1082, 1999. PMID 10071303
86. Nass SJ and Davidson NE. The biology of breast cancer. *Hematol. Oncol. Clin. North Am.* 13:311-332, 1999. PMID 10363133
87. Wolff AC and Davidson NE. New data on adjuvant therapy for breast cancer. *Curr. Oncol. Rep.* 1:31-37, 1999. PMID 11122795
88. Nass SJ, Ferguson AT, El-Ashry D, Nelson WG, and Davidson NE. Expression of DNA methyltransferase (DMT) and the cell cycle in human breast cancer cells. *Oncogene.* 18:7453-7461, 1999. PMID 10602504
89. McCloskey DE, Woster PM, Casero, Jr. RA, and Davidson NE. Effects of the polyamine analogs CPENSpm and CHENSpm in human prostate cancer cells. *Clinical Cancer Res.* 6:17-23, 2000. PMID 10656427.
90. Wolff AC and Davidson NE. Primary systemic therapy in breast cancer. *J. Clin. Oncol.* 18:1558-1569, 2000. PMID 10735905
91. Jackisch C, Hahm HA, Tombal B, McCloskey D, Butash K, Davidson NE and Denmeade SR. Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells. *Clin Cancer Res.* 6:2844-2850, 2000. PMID 10914733
92. Carlson RW, Anderson BO, Bensinger W, Cox CE, Davidson NE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Licher AS, McCormick B, Nabell LM, Reed EC, Silver SM, Smith ML, Somlo G, Theriault R, Ward JH, Winer EP, Wolff A; National Comprehensive Cancer Network. NCCN Practice Guidelines for Breast Cancer. *Oncology* (Williston Park). 14(11A):33-49, 2000. PMID 11195418.
93. Hahm HA, Armstrong DK, Chen T-L, Grochow LB, Goodman SN, Davidson NE and Kennedy MJ. Novobiocin in combination with high-dose chemotherapy for the treatment of advanced breast cancer: a phase 2 study. *Biology of Blood and Marrow Transplantation.* 6:335-343, 2000. PMID 10905771
94. Nass SJ, Herman JG, Gabrielson E, Iversen PW, Parl FF, Davidson NE, and Graff JR. Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. *Cancer Res.* 60:4346-4348, 2000. PMID 10969774
95. van der Wall E, Horn T, Bright E, Passos-Coehlo JL, Bond S, Clarke B, Altomonte V, McIntyre K, Vogelsang G, Noga SJ, Davis JM, Thomassen J, Oly KV, Lee SM, Fetting J, Armstrong DK, Davidson NE, Hess AD and Kennedy MJ. Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells. *Br. J. Cancer.* 83:1405-1411, 2000. PMC2363431

96. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG and Davidson NE. Transcriptional activation of estrogen receptor α in human breast cancer cells by histone deacetylase inhibition. *Cancer Res.* 60:6890-6894, 2000. PMID 11156387
97. Anderson BO, Bensinger W, Cox CE, Davidson NE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Lichten AS, McCormick B, Nabell LM, Reed EC, Silver SM, Smith ML, Somio G, Theriault R, Ward JH, Winer EP and Wolff A. NCCN practice guidelines for breast cancer. *Oncology (Huntingt)* 14:33-49, 2000. PMID 11195418
98. Wolff AC and Davidson NE. Early operable breast cancer. *Curr Treat Options Oncol.* 1(3): 210-220, 2000. PMID 12057163
99. Hahm HA, Dunn VR, Butash KA, Deveraux WL, Woster PM, Casero RA, Jr., and Davidson NE. Combination of standard cytotoxic agents with polyamine analogs in the treatment of breast cancer cell lines. *Clin. Cancer Res.* 7:391-399, 2001. PMID 11234895
100. Yan L, Yang X and Davidson NE. Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. *J. Mammary Gland Biol. Neoplasia.* 6:183-192, 2001. PMID 11501578
101. Yang X, Yan L and Davidson NE. DNA methylation in breast cancer. *Endocrine-Related Reviews.* 8:115-127, 2001. PMID 11446343
102. Dees EC and Davidson NE. Ovarian ablation as adjuvant therapy for breast cancer. *Seminars in Oncology.* 28:322-33, 2001. PMID 11498826
103. Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, Soito AB, Hung DT, Ljung B-M, Davidson NE and Sukumar S. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. *The Lancet.* 357:1335-1336, 2001. PMID 11343741
104. Davidson NE. Ovarian ablation as adjuvant therapy for breast cancer. *J. Natl. Cancer Inst. Monograph.* 30:67-71, 2001. PMID 11773295
105. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, and Davidson NE. Synergistic activation of functional estrogen receptor (ER)- α by DNA methyltransferase and histone deacetylase inhibition in human ER- α -negative breast cancer cells. *Cancer Res.* 61:7025-7029, 2001. PMID 11585728
106. Wolff AC and Davidson NE. Use of SERMs for the adjuvant therapy of early-stage breast cancer. *Ann N Y Acad Sci.* 949:80-88, 2001. PMID 11795384
107. Armstrong, D.K. and Davidson, N.E. Dose intensity for breast cancer. *Breast Disease.* 14:91-97, 2001. PMID 15687639
108. Wolff AC and Davidson NE. Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease. *The Oncologist* 7:239-245, 2002. PMID 12065797.
109. Emens LA, Kennedy MJ, Fetting JH, Davidson NE, Garrett E and Armstrong DK. A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer. *Breast Cancer Res Treat.* 76:145-156, 2002. PMID 12452452
110. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN and Perez EA. Concordance between local and central laboratory HER 2 testing in the Breast Intergroup Trial N9831. *J Natl Cancer Inst.* 94:855-7, 2002. PMID 12048274

111. Keen JC and Davidson NE. The biology of breast cancer. *Cancer*. 97 (3 supp): 825-833, 2003. PMID 12548582
112. Visvanathan K and Davidson NE. Aromatase inhibitors as adjuvant therapy in breast cancer. *Oncology*. 17:335-42, 2003. PMID 19577386
113. Citron ML, Berry DA, Cirrincione C, Hudis C, Winder EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung E, Abrams J, Schilsky RL, Muss HB and Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial 9741/Cancer and Leukemia Group B trial 9741. *J Clin Oncol*. 21:1431-9, 2003. PMID 12668651
114. Yan L, Nass SJ, Smith D, Nelson WG, Herman JG and Davidson NE. Specific inhibition of DNMT 1 by antisense oligonucleotides induces re-expression of estrogen receptor alpha (ER) in ER-negative human breast cancer cell lines. *Cancer Biology and Therapy*. 2:552-6, 2003. PMID 14614325
115. Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D and Davidson NE. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER-negative human breast cancer cells in combination with 5-aza-2' deoxycytidine. *Breast Cancer Res Treatment*. 81:177-86, 2003. PMID 14620913
116. Wolff AC, Armstrong DK, Fetting JH, Carducci MK, Riley CD, Bender JF, Casero, Jr. RA, and Davidson NE. A phase II study of the polyamine analog N1-N11-diethylnorspermine daily for five days every 21 days in patients with previously treated metastatic breast cancer. *Clinical Cancer Res*. 9:5922-5928, 2003. PMID 14676116
117. Davidson NE, Visvanathan K, Emens L. New findings about endocrine therapy for breast cancer. *The Breast*. 12:368-372, 2003. PMID 14659107
118. Zhu K, Davidson NE, Hunter S, Yang X, Payne-Wilks K, Roland CL, Phillips D, Bentley C, Dai M, Williams SM. Methyl-group dietary intake and risk of breast cancer among African-American women: a case-control study by methylation status of the estrogen receptor alpha gene. *Cancer Causes Control*. 14:827-836, 2003. PMID 14682440
119. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ and Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. *N Engl J Med*. 349:1793-1802, 2003. PMID 14551341
120. Emens LA and Davidson NE. The follow-up of breast cancer. *Semin Oncol*. 338-348, 2003. PMID 12870135
121. Huang Y, Hager ER, Phillips DL, Dunn VR, Hacker A, Frydman B, Kink JA, Valasinas AL, Reddy VK, Marton LJ, Casero RA,Jr. and Davidson NE. A novel polyamine analog inhibits growth and induces apoptosis in human breast cancer cells. *Clin Cancer Res*. 9:2769-2777, 2003. PMC3625930
122. Kumar SK, Hager E, Pettit C, Gurulingappa H, Davidson NE and Khan SR. Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. *J Med Chem*. 46:2813-2815, 2003. PMID 12825923

- 123.Emens LA and Davidson NE. Adjuvant hormonal therapy for premenopausal women with breast cancer. *Clin Can Res.* 9(1 Pt 2):486S-94S, 2003. PMID 12538505.
- 124.Come SE, Buzdar AU, Arteaga CL, Brodie AM, Davidson NE, Dowsett M, Ingle JN, Johnston SR, Lee AV, Osborne CK, Pritchard KI, Vogel VG, Winer EP and Hart CS. Second international conference on recent advances and future directions in endocrine manipulation of breast cancer: summary consensus statement. *Clin Cancer Res.* 9(1 Pt 2) 443S-446S, 2003. PMID 12538498
- 125.Yang X, Groshen S, Formenti SC, Davidson NE and Press MF. P7 antigen expression in human breast cancer. *Clin Cancer Res.* 9:201-206, 2003. PMID 12538470.
- 126.Huang Y, Keen JC, Hager E, Smith R, Frydman B, Valasinas AL, Reddy VK, Marton LJ, Casero, Jr. RA and Davidson NE. Regulation of polyamine analogue cytotoxicity by c-jun in human MDA-MB-435 cancer cells. *Molecular Cancer Res.* 2:81-88, 2004. PMID 14985464
- 127.Stearns V, Davidson NE and Flockhart DA. Pharmacogenetics in the treatment of breast cancer. *The Pharmacogenomics Journal.* 4:143-53, 2004. PMID 15024382
- 128.Gabrielson E, Tully E, Hacker A, Pegg A, Davidson N and Casero R. Induction of spermidine/spermine N1-acetyltransferase (SSAT) in breast cancer tissues treated with the polyamine analogue N1-N11-diethylnorspermine. *Cancer Chemotherapy Pharmacol.* 54:122-6, 2004. PMID 15138709
- 129.Emens LA, Armstrong D, Biedrycki B, Davidson NE, Sproul-Davis, Janice, Fetting, John, Jaffee E, Onmers B, Piantadosi S, Reilly RT, Stearns V, Tartakovsky I, Visvanathan K and Wolff A. A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. *Human Gene Therapy* 15:313-337, 2004. PMID 15018740
- 130.Prowell TM and Davidson NE. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? *The Oncologist* 9:507-17, 2004. PMID 15477635
- 131.Emens LA and Davidson NE. Trastuzumab in breast cancer. *Oncology* 18: 1117-1138, 2004. PMID 15471197.
- 132.Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Ingle JN, Rodeheffer RJ, Gersh BJ, Jaffe AS. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup adjuvant trial. *J Clin Oncol.* 22:3700-4, 2004. PMID 15365066
- 133.Mock V, Frangakis C, Davidson NE, Ropka ME, Pickett M, Poniatowski B, Stewart K, Cameron L, Zawacki K, Podewils LJ, Cohen G and McCorkle R. Exercise manages fatigue during breast cancer treatment: a randomized controlled trial. *Psycho-Oncology* 14:464-77, 2005. PMID 15484202
- 134.Jacobs MA, Ouwerkerk R, Wolff AC, Stearns V, Bottomley PA, Barker PB, Argani P, Khouri N, Davidson NE, Bhujwalla ZM, and Bluemke DA. Multiparametric and multinuclear magnetic resonance imaging of human breast cancer: current applications. *Technology in Cancer Research & Treatment* 3:543-50, 2004. PMID 15560711

- 135.Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, and Davidson NE. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Group trial E2196. *J Clin Oncol* 22:4683-90, 2004. PMID 15570070
- 136.Keen JC, Garrett-Mayer E, Pettit C, Mack KM, Manning J, Herman JG, and Davidson NE. Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells. *Cancer Biol Ther* 3:1304-12, 2004. PMID 15662126
- 137.Huang Y, Pledgie A, Casero RA and Davidson NE. Molecular mechanisms of polyamine analogues in cancer cells, *Anti-Cancer Drugs* 16: 229-41, 2005. PMID 15711175
- 138.Davis-Sproul JM, Harris MP, Davidson NE, Kobrin BJ, Jaffee EM, and Emens LA. Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility. *Cytotherapy* 1:46-56, 2005. PMID 16040383
- 139.Agoston AT, Argani P, Yegnasubramanian S, De Marzo AM, Ansari-Lari MA, Hicks JL, Davidson NE, Nelson WG. Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. *J Biol Chem.* 280:18302-10, 2005. PMID 15755728
- 140.Sharma D, Blum J, Yang X, Beaulieu N, Macleod AR, Davidson NE. Release of methyl CpG binding proteins and histone deacetylase 1 from the estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. *Mol Endocrinol* 19:1740-51, 2005. PMID 15746193
- 141.Goss P, Ingle J, Martino S, Robert N, Muss H, Piccart M, Castiglione M, Tu D, Shepherd L, Pritchard K, Livingston R, Davidson NE, Norton L, Perez E, Abrams J, Cameron DA, Palmer M, Pater J. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor positive breast cancer: NCIC CTG MA.17. *J Natl Cancer Inst.* 97:1262-71, 2005. PMID 16145047
- 142.Davidson NE, O'Neill AM, Vukov AM, Osborne CK, Martino S, White DR, and Abeloff MD. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). *J Clin Oncol* 23:5973-82, 2005. PMID 16087950
- 143.Huang Y, Pledgie A, Rubin E, Marton LJ, Woster PM, Casero RA, and Davidson NE. Role of p53/p21Waf1/Cip1 in the regulation on polyamine analogue-induced growth inhibition and cell death in human breast cancer cells. *Cancer Biol Ther*, 4:1006-13, 2005. PMC 3639297. NIHMS 453467
- 144.Keen JC, Zhou Q, Park BH, Pettit C, Mack KM, Blair B, Brenner K, and Davidson NE. Protein phosphatase 2A regulates estrogen receptor alpha (ER) expression through modulation of ER mRNA stability. *J Biol Chem* 280:29519-24, 2005. PMID 15965230.
- 145.Li J, Orlandi R, White CN, Rosenzweig J, Zhao J, Seregni E, Morelli D, Yu Y, Meng XY, Zhang Z, Davidson NE, Fung ET, and Chan DW. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. *Clin Chem.* 51:2229-35, 2005. PMID 16223889
- 146.Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N Engl J Med.* 353:1673-84, 2005. PMID 16236738

147. Wolff AC, O'Neill A, Kennedy MJ, Stewart JA, Gradishar WJ, Lord RS 3rd, Davidson NE, Wood WC. Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of Eastern Cooperative Oncology Group trial E8193. *Clin Breast Cancer*. 4:334-9, 2005. PMID 16277884
148. Pledgie A, Huang Y, Hacker A, Zhang Z, Woster PM, Davidson NE, Casero RA Jr. Spermine oxidase SMO (PAOh1), not N1-acetylpolyamine oxidase PAO, is the primary source of cytotoxic H₂O₂ in polyamine analogue-treated human breast cancer cell lines. *J Biol Chem*. 280: 39843-51, 2005. PMID 16207710
149. Davidson NE, Morrow M, Kopans DB, Koerner FC. Case records of the Massachusetts General Hospital. Case 35-2005. A 56-year-old woman with breast cancer and isolated tumor cells in a sentinel lymph node. *N Engl J Med*. 353: 2177-85, 2005. PMID 16291988
150. Yager JD and Davidson NE. Estrogen carcinogenesis in breast cancer. *N Engl J Med*, 354:270-82, 2006. PMID 16421368
151. Zucker S, Wang M, Sparano JA, Gradishar WJ, Ingle JI, Davidson NE. Plasma MMP-7 and MMP-9 in patients with metastatic breast cancer treated with marimastat or placebo: Results of an Eastern Cooperative Oncology Group Trial (E2196). *Clinical Breast Cancer*; 6:525-9, 2006. PMID 16595036
152. Modzelewska A, Pettit C, Achanta G, Davidson NE, Huang P, Khan SR. Anticancer activities of novel chalcone and bis-chalcone derivatives. *Bioorg Med Chem*. 14:3491-5, 2006. PMID 16434201
153. Ingle JI, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Duration of letrozole treatment and outcomes in the placebo-controlled NCIG CTG MA.17 extended adjuvant therapy trial. *Breast Cancer Res Treat*, 99:295-300, 2006. PMID 16541302
154. Carlson RW, O'Neill A, Goldstein L, Sikic BI, Abramson N, Stewart JA, Davidson NE, Wood WC., A pilot phase II trial of valsphospor modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): A trial of the Eastern Cooperative Oncology Group. *Cancer Investigation* 24:677-81, 2006. PMID 17118777
155. Fackler MJ, Malone K, Zhang Z, Schilling E, Garrett-Mayer E, Swift-Scanlon T, Lange J, Nayar R, Davidson NE, Khan SA, Sukumar S. Quantitative multiplex-methylation specific PCR analysis doubles detection of tumor cells in breast ductal fluid. *Clinical Cancer Res*, 12:3306-10, 2006. PMID 16740751
156. Huang Y, Keen JC, Pledgie A, Marton LJ, Zhu T, Sukumar S, Park BH, Blair B, Brenner K, Casero RA Jr, Davidson NE. Polyamine analogues down-regulate estrogen receptor alpha expression in human breast cancer cells. *J Biol Chem*. 281:19055-63, 2006. PMC3623667
157. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup adjuvant trial. *J Clin Oncol*. 24:3032-8, 2006. PMID 16809727
158. Brown RJ, Davidson, NE, Adjuvant hormonal therapy for premenopausal women with breast cancer. *Seminars in Oncology*. 33:657-663, 2006. PMID 17145345

159. Khatcheressian JL, Wolff AC, Smith TJ, Greenfield E, Muss HB, Vogel VG III, Halberg F, Somerfield MR, Davidson NE. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting, *J Clin Oncol.* 24:5091-5097, 2006. PMID 17033037
160. Wolff AC, Jones RJ, Davidson NE, Jeter SC, Stearns V. Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. *J Clin Oncol* 5:24: 2392-4, 2006. PMIC 16710041
161. Sharma D, Saxena NK, Davidson NE, Vertino PM, Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. *Cancer Res.* 66:6370-8, 2006. PMC2925469
162. Abukhdeir AM, Blair BG, Brenner K, Karakas B, Konishi H, Lim J, Sahasranaman V, Huang Y, Keen J, Davidson N, Vitolo MI, Bachman KE, Park BH. Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells. *Breast Cancer Res Treat.* 99:23-33, 2006. PMID 16541319
163. Visvanathan K, Santor D, Ali SZ, Hong IS, Davidson NE, Helzlsouer KJ. The importance of cytologic intrarater and interrater reproducibility: the case of ductal lavage. *Cancer Epidemiol Biomarkers Prev.* 15:2553-6, 2006. PMID 17164385
164. Zhou Q, Atadja P, Davidson NE. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. *Cancer Biol Ther.* 6:64-69, 2007. PMID 17172825
165. Pledgie-Tracy A, Sobolewski MD, Davidson NE. Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. *Mol Cancer Ther.* 6:1013-1021, 2007. PMID 17339367
166. Visvanathan K, Santor D, Ali SZ, Brewster A, Arnold A, Armstrong DK, Davidson NE, Helzlsouer KJ. The reliability of nipple aspirate and ductal lavage in women at increased risk for breast cancer – a potential tool for breast cancer risk assessment and biomarker evaluation. *Cancer Epidemiol Biomarkers Prev.* 16:950-5, 2007. PMID 17507621
167. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. *J Clin Oncol.* 25:2006-11, 2007. PMID 17452676
168. Briest S, Davidson NE. Aromatase inhibitors for breast cancer. *Rev Endocr Metab Disord.*, 8:215-28, 2007. PMID 17486453
169. Cornblatt BS, Ye L, Dinkova-Kostova AT, Erb M, Fahey JW, Singh NK, Chen MS, Stierer T, Garrett-Meyer E, Argani P, Davidson NE, Talalay P, Kensler TW, Visvanathan K. Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. *Carcinogenesis.* 28:1485-90, 2007. PMID 17347138
170. LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Sainsbury R. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive

- breast cancer: a metaanalysis of individual patient data from randomized adjuvant trials. Lancet 369: 1711-23, 2007. PMID 17512856
- 171.Sui M, Huang Y, Park BH, Davidson NE, Fan W. Estrogen receptor α mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res. 67:5337-44, 2007. PMID 17545614
- 172.Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cell D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N Engl J Med 357:2666-76, 2007. PMID 18160686
- 173.Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner J, Demetri GD, Curran W Jr, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey S, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Davidson NE, Schilsky RL, Lichten AS. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening. A report from the American Society of Clinical Oncology. J Clin Oncol 26:313-25, 2008. PMID 18086794
- 174.Stearns V, Zhou Q, Davidson NE. Epigenetic regulation as a new target for breast cancer therapy. Cancer Invest 25:659-65, 2007. PMID 18058459
- 175.Bao T, Davidson NE. How we maintain bone health in early stage breast cancer patients on aromatase inhibitors, J Oncology Practice 3:323-5, 2007. PMC2793755
- 176.Bao T, Davidson NE. Adjuvant endocrine therapy for premenopausal women with early breast cancer. Breast Cancer Research 9:115-7, 2007. PMC2246185
- 177.Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer completing 5 years of tamoxifen. J Clin Oncol 26:1948-55, 2008. PMID 18332475
- 178.Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA, Gersh BJ, Jaffe AS, and Rodeheffer RJ. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-8, 2008. PMC 4048960, NIHMS 589003
- 179.Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ, Piccart MJ, Castiglione M, Shpeher LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 19:877-82, 2008. PMID 18332043
- 180.Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu M-L, Rowley SC , Shak SA , Perez ED, Shulman LJ, Martino SG, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA. Estrogen and progesterone receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratories. J Clin Oncol 26:2473-81, 2008. PMID 18487567
- 181.Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor E, Teo WW, Griffin C, Fetting J, Davidson NE, Demarzo AM, Hicks JL, Chitale D, Ladanyi M, Sukumar S, Argani P.

- Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. *Clinical Cancer Res* 14:1938-46, 2008. PMC2965068
- 182.Zhou Q, Agoston AT, Atadja P, Nelson V WG, and Davidson NE. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells, *Molecular Cancer Res* 6:873-83, 2008. PMC3361136
- 183.Goldstein L, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson N, Sledge G, Perez E, Shulman L, Martino S, Sparano JA. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. *J Clin Oncol* 26:4063-71, 2008. PMC2654377
- 184.Goldstein LJ, O'Neill AM, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0-3 positive axillary nodes: results of North American Breast Cancer Intergroup Trial E2197, *J Clin Oncol* 26:4092-9, 2008. PMC2654376
- 185.Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD. Association of VEGF and VEGFR-2 genetic polymorphisms with outcome in E2100. *J Clin Oncol* 26:4672-8, 2008. PMC2653128
- 186.Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge Jr GW, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. *N Engl J Med* 358:1663-71, 2008. PMID 18420499. PMC2743943
- 187.Davidson NE. Tracking 35 years of progress against breast cancer. *Oncology* 22(6):593-53, 2008. PMID 18561549.
- 188.Arteaga CL, O'Neill A, Moulder SL, Pins M, Sparano JA, Sledge GW, and Davidson NE. A phase I-II study of combined blockade of the erbB receptor network with trastuzumab and gefitinib in patients with HER2 (erbB-2)-overexpressing metastatic breast cancer. *Clin Cancer Res* 14:6277-6283, 2008. PMC2925197
- 189.Bao T, Davidson NE. Gene expression profiling of breast cancer. *Adv Surg*; 42:249-60, 2008. PMC2775529
- 190.Fall-Dickson JM, Mock V, Berk RA, Grimm, PM, Davidson N, Gaston-Johansson F. Stomatitis-related pain in women with breast cancer undergoing autologous hematopoietic stem cell transplant. *Cancer Nurs*. 31:452-61, 2008. PMC3508511
- 191.Carraway HE, Wang S, Blackford A, Guo M, Powers P, Jeter S, Davidson NE, Argani P, Terrell K, Herman JG, Lange JR. Promoter hypermethylation in sentinel lymph nodes as a marker for breast cancer recurrence. *Breast Cancer Res Treat* 114:315-25, 2009. PMC3422075
- 192.Shabeer S, Sobolweski M, Anchoori R, Kachhap S, Davidson N, Carducci M, Khan SR. Fenugreek: A naturally occurring edible spice as an anticancer agent. *Cancer Biol Ther* 8: 3, 272-8, 2009. PMC3095649

- 193.Halyard MY, Pisansky TM, Dueck A, Pierce LG, Solin LJ, Marks LB, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Dakhil DR, Perez EA. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the North Central Cancer Treatment Group Phase 3 trial N9831. *J Clin Oncol*. Jun 1:27: 2638-44, 2009. PMID2690390
- 194.Higgins MJ, Davidson NE. What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer? *Curr Oncol Rep*. 11:45-50, 2009. PMID 19080741
- 195.Billam M, Witt AE, Davidson NE. The silent estrogen receptor: Can we make it speak? *Cancer Biology & Therapy* 8:6, 485-496, 2009. PMC 3901993, NIHMS 529864
- 196.Zellars R, Stearns V, Frassica D, Asrari F, Tsangaris T, Lyers L, DiPasquale S, Lange JR, Jacobs LK, Emens L, Armstrong DK, Fetting JH, Garrett-Mayer E, Davidson NE, Wolff AC. Feasibility trial of partial breast irradiation and concurrent dose-dense doxorubicin and cyclophosphamide. *J Clin Oncol* 27:2816-22, 2009. PMID 19332718
- 197.Hughes LL, Wang M, Page DL, Gray R, Solin LJ, Davidson NE, Lowen MA, Ingle JN, Recht A, Wood WC. Local excision alone with irradiation for ductal carcinoma in situ of the breast: A trial of the Eastern Cooperative Oncology Group. *J Clin Oncol*, 27:5319-24, 2009. PMC2773217
- 198.Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrick S, Laiko M, Levi J, Daphtry MM, Biedrzycki B, Wolff AC, Stearns V, Disis ML, Ye X, Piantadosi S, Fetting JH, Davidson NE, Jaffee EM. Time sequential treatment with cyclophosphamide, doxorubicin and an allogeneic granulocyte-macrophage colony-stimulating factor secreting breast tumor vaccine: A chemotherapy dose-ranging factorial study of safety and immune activation. *J Clin Oncol*. 27:5911-8, 2009. PMC2793039
- 199.Billam M, Sobolewski MD, Davidson NE. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. *Breast Cancer Res Treat*, 120:581-92, 2010. PMC 3901992, NIHMS 529877
- 200.Balmanoukian A, Zhang Z, Jeter S, Slater S, Armstrong DK, Emens LA, Fetting JH, Wolfe AC, Davidson NE, Jacobs L, Lanage J, Tsangaris TN, Zellars R, Gabrielson E, Stearns V. African American women who receive primary anthracycline-and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. *J. Clin. Oncol.* 27:e35-7, 2009. PMID 19564528.
- 201.Zhou Q, Shaw PG, Davidson NE. Epigenetics meets estrogen receptor: regulation of estrogen receptor by direct lysine methylation. *Endocr Relat Cancer* 16:316-23, 2009. PMC 3901989, NIHMS 529886
- 202.Zhou Q, Shaw PG, Davidson NE. Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. *Breast Cancer Res Treat* 117:443-51, 2009. PMID 18683042
- 203.Madar I, Huang Y, Ravert H, Dalrymple SL, Davidson NE, Isaacs JT, Dannals RF, Frost JJ. Detection and quantification of the evolution dynamics of apoptosis using the PET voltage sensor 18F-fluorobenzyl triphenyl phosphonium. *J. Nucl Med*; 50:774-80, 2009. PMID 19372481

- 204.Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez E, Shulman LN, Martino S, Davidson NE, Sledge GW Jr, Gray R. Relationship between topoisomerase 2A RNA expression and recurrence after adjuvant chemotherapy for breast cancer. *Clin Cancer Res* Dec 15:7693-7700, 2009. PMC3396025
- 205.Emens LA, Davidson NE. Post operative endocrine therapy for invasive breast cancer. *Cancer Treat Res.* 151:139-61, 2009. PMC3086398
- 206.Puhalla S, Brufsky A, Davidson NE. Adjuvant endocrine therapy for premenopausal women with breast cancer. *Breast* 18:2122-30, 2009
- 207.Pledgie-Tracy, A, Billam M, Hacker A, Sobolewski MD, Woster PM, Zhang Z, Casero RA, Davidson NE. The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines. *Cancer Chemother Pharmacol*, 65: 1067, 2010. PMC2840063
- 208.Yao Y, Li H, Gu Y, Davidson NE, Zhou Q. Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling. *Carcinogenesis* 31:382-387, 2010: PMC2832546
- 209.Zhou Q, Chaerkady R, Shaw PG, Kensler TW, Pandey A, Davidson NE. Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. 2010 Jan 4. *Proteomics*. 10:1029-39, 2010. PMC3337220
- 210.Yao Y, Brodie AM, Davidson NE, Kensler TW, Zhou Q. Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. *Breast Cancer Res Treat.* 121:111-20, 2010. PMC3417311
- 211.Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborn CK, Hayes DF; for the Breast Cancer Intergroup of North American. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomized trial. *Lancet Oncol.* 11:55-65, 2010 PMC3058239
- 212.King JC, Lawrence TS, Murphy SB, Davidson NE, Mayer RJ. The American Society of Clinical Oncology Cancer Foundation Grants Program: a 25-year report and a look toward the future. *J Clin Oncol* 28:1616-21, 2010. PMID: 20177012
- 213.Wolff AC, Wang M, Li H, Pins MR, Pretorius FJ, Rowland KM, Sparano JA, Davidson NE. Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198. *Breast Cancer Res Treat*; 121:111-20, 2010. PMC3112234
- 214.Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. *J Clin Oncol* 28:3784-96, 2010 PMID 20625130
- 215.Perez E, Reinholtz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. *J Clin Oncol.* 28:4307-15, 2010. PMC2954132
- 216.Jacobs MA, Stearns V, Wolff AC, Macura K, Argani P, Khouri N, Tsangaris T, Barker PB, Davidson NE, Bhujwalla ZM, Bluemke DA, Ouwerkerk R. Multiparametric magnetic

- resonance imaging spectroscopy and multinuclear (^{23}Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. *Acad Radiol* 17:1477-85, 2010. PMC3401079
217. Davidson, NE. HER2-targeted therapies: how far we've come—and where we're headed. *Oncology* 25(5):425-6, 2011. PMID 21710840
218. Davidson, NE. Retrospective on the last quarter-century in medical oncology. *Oncology* 25(5):396, 2011. PMID 21710831
219. Connolly RM, Rudek MA, Garrett-Mayer E, Jeter SC, Donehower MG, Wright LA, Zhao M, Fetting JH, Emens LA, Stearns V, Davidson NE, Baker SD, Wolff AC. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. *Breast Cancer Res Treat*, 127(1):153-62, 2011. PMC3111459
220. Perez EA, Jenkins RB, Dueck AC, Wiktor AE, Bedroske PP, Anderson SK, Ketterling RP, Sukov WR, Kanehira K, Chen B, Geiger XJ, Andorfer CA, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Jutteh LA, Gralow JR, Harris LN, Ingle JN, Lingle WL, Reinholtz MM. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the North Central Cancer Treatment Group N9831 adjuvant trastuzumab trial. *J Clin Oncol* 29(6):651-9, 2011. PMID 2124520
221. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Jejewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. *J Clin Oncol* 29(34):4491-7, 2011. PMC3236650
222. Shaw PG, Chaerkady R, Zhang Z, Davidson NE, Pandey A. Monoclonal antibody cocktail as an enrichment tool for acetylome analysis. *Anal Chem* 83(10):3623-6, 2011. PMC3205458
223. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson, NE, Geyer CE Jr., Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. *J Clin Oncol*. 29(25):3366-73, 2011. PMC3164242
224. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez EA, Shulman LN, Martino S, Davidson NE, Kenny PA, Sledge GW Jr, Gray R. Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. *Clin Cancer Res*. 17(22):7194-7203, 2011. PMC3570203
225. Huang Y, Shaw PG, Davidson NE. Inhibition of histone deacetylases. *Methods Mol Biol* 791:297-311, 2011. PMID 21913088
226. Huang Y, Nayak S, Jankowitz R, Davidson NE, Oesterreich S. Epigenetics in breast cancer: what's new? *Breast Cancer Res*. 13(6):225, 2011. PMC3326545
227. Griggs JJ, Somerfield MR, Anderson H, Henry NL, Hudis CA, Khatcheressian JL, Partridge AH, Prestrud AA, Davidson NE. American Society of Clinical Oncology endorsement of the Cancer Care Ontario practice guidelines on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer. *J Clin Oncol* 29(29): 3939-42, 2011. PMID 21900112

228. Prowell TM, Blackford AL, Byrne C, Khouri NF, Dowsett M, Folkerd E, Tarpinian KS, Powers PP, Wright LA, Donehower MG, Jeter SC, Armstrong DK, Emens LA, Fetting JH, Wolff AC, Garrett-Mayer E, Skaar TC, Davidson NE, Stearns V. Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. *Cancer Prev Res (Phila)*, 4:1993-2001, 2011. PMC3700336
229. Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. *J Clin Oncol*. 29(34):4491-7, 2011. PMC3236650
230. Shaw PH, Boyiadzis M, Tawbi H, Welsh A, Kemerer A, Davidson NE, Kim Ritchey A. Improved clinical trial enrollment in adolescent and young adult (AYA) oncology patients after the establishment of an AYA oncology program uniting pediatric and medical oncology divisions. *Cancer* 10, 15:118(14):3614-7, 2012. PMID 22213134
231. Jin K, Kong X, Shah T, Penet MF, Wildes F, Sgroi DC, Ma XJ, Huang Y, Kallioniemi a, Landberg G, Bieche I, Wu X, Lobi PE, Davidson NE, Bhujwalla ZM, Zhu T, Sukumar S. The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. *Proc Natl Acad Sci*, 109(8):2736-41, 2012. PMC3286915
232. Agyeman AS, Chaerkady R, Shaw PG, Davidson NE, Visvanathan K, Pandey A, Kensler TW. Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles. *Breast Cancer Res Treat*, 132(1): 175-87, 2012. PMC3564494
233. Huang Y, Vasilatos SN, Boric L, Shaw PG, Davidson NE. Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells. *Breast Cancer Res Treat*, 131(3):777-89, 2012. PMC3624096
234. Bardia A, Arieas ET, Zhang Z, DeFilippis A, Tarpinian K, Jeter S, Nguyen A, Henry NL, Flockhart DA, Hayes DF, Hayden J, Hayden J, Storniolo AM, Armstrong DK, Davidson NE, Fetting J, Ouyang P, Wolff AC, Blumenthal RS, Ashen MD, Stearns V. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. *Breast Cancer Res Treat*. 131(3):907-14, 2012. PMC3582017
235. Zhu Q, Huang Y, Marton LJ, Woster PM, Davidson NE, Casero RA Jr. Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. *Amino Acids*. 42(2-3):887-98, 2012. PMC3240695
236. Higgins MJ, Prowell TM, Blackford AL, Byrne C, Khouri NF, Slater SA, Jeter SC, Armstrong DK, Davidson NE, Emens LA, Fetting JH, Powers PP, Wolff AC, Green H, Thibert JN, Rae JM, Folkerd E, Dowsett M, Blumenthal RS, Garber JE, Stearns V. A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. *Breast Cancer Res Treat*. 131(3):915-24, 2012. PMC3536477
237. Perez EA, Dueck AC, McCullough AE, Reinholtz MM, Tenner KS, Davidson NE, Gralow J, Harris LN, Kutteh LA, Hillman DW, Jenkins RB, Chen B. Predictability of adjuvant

- trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. *J Natl Cancer Inst.* 18:104(2):159-62. 2012. PMC3260130
- 238.Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. *J Natl Cancer Inst* 104(5) 406-14, 2012. PMID 22250182. PMC3295746
- 239.Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge W Jr, Wood WC, Fetting J, Davidson NE. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. *Cancer* 118(23):5937-46, 2012. PMC3586227
- 240.Hu D, Zhou Z, Davidson NE, Huang Y, Wan Y. Novel insight into KLF4 proteolytic regulation in estrogen receptor signaling and breast carcinogenesis. *J Biol Chem* 287(17) 13584-97, 2012. PMC3340146
- 241.Puhalla S, Battacharya S, Davidson NE. Hormonal therapy in breast cancer: A model disease for the personalization of cancer care. *Mol Oncol.* 6(2):222-36, 2012. PMID 22406404
- 242.Puhalla S, Battacharya S, Davidson NE. Hematopoietic growth factors: Personalization of risks and benefits. *Mol Oncol* 6(2):237-41, 2012. PMID 22497867
- 243.Sparano JA, Goldstein LJ, Davidson NE, Sledge GW Jr, Gray R. TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. *Breast Cancer Res Treat.* 134(2):751-7, 2012. PMID 22706628
- 244.Solin LJ, Gray R, Goldstein LJ, Recht A, Baehner FL, Shak S, Badve S, Perez EA, Shulman LN, Martino S, Davidson NE, Sledge GW Jr, Sparano JA. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. *Breast Cancer Res Treat* 134(2):683-92, 2012. PMC3552372
- 245.Schneider BP, Zhao F, Wang M, Steans V, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE, Sparano JA. Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. *J Clin Oncol* 30(25):3051-7, 2012. PMC3732004
- 246.Zhu Q, Jin L, Casero RA, Davidson NE, Huang Y. Role of ornithine decarboxylase in regulation of estrogen receptor alpha expression and growth in human breast cancer cells. *Breast Cancer Res Treat*, 136(1):57-66, 2012. PMC3715085
- 247.Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Livingston RB, Davidson NE, Perez EA, Chavarri-Guerra Y, Cameron DA, Pritchard KI, Whelan T, Shepherd LE, Tu D. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. *Ann Oncol.* (2):355-61, 2013. PMC3551482
- 248.Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfield H, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE. Breast Cancer Follow-up and management after primary treatment: American Society of

- Clinical Oncology Clinical Practice Guidelines Update. *J Clin Oncol*, 31(7):961-5, 2013. PMID 23129741.
- 249.Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, Davidson N, Goldstein LJ, Miller KD, Sparano JA. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: Little evidence of improvement over the past 30 years. *Cancer*. 15:119(6):1140-8, 2013. PMC 3593800
- 250.Schneider BP, Gray FJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Schenkler TN, Vang Nielsen K, Muller S, Thor A, Sledge GW Jr, Sparano JA, Davidson NE, Badve SS. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. *Clin Cancer Res* 1:19(5):1281-9, 2013. PMC 3594423
- 251.Vasilatos SN, Katz TA, Oesterreich S, Wan Y, Davidson NE, Huang Y. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. *Carcinogenesis* 34(6):1196-207, 2013. PMC3670252
- 252.Rudek MA, Connolly RM, Hoskins JM, Garrett-Mayer E, Jeter SC, Armstrong DK, Fetting JH, Stearns V, Wright LA, Zhao M, Watkins SP Jr., McLeod HL, Davidson NE, Wolff AC. Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. *Breast Cancer Res Treat*. 139(1):135-43, 2013. PMC3673300
- 253.Solin LJ, Gray R, Baehner, FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW Jr, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. *J Natl Cancer Inst* 15;105(10):701-10, 2013. PMC3653823
- 254.Davidson NE. Fifteen years of anti-HER2 therapy. *Oncology* 27(3):151, 2013. PMID 23687781
- 255.Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB, Lingle WL, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris LN, Gralow JR, Reinholtz MM. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the north central cancer treatment group N9831 trial. *J Clin Oncol* 31(17):2115-22, 2013. PMC3731983
- 256.Stearns V, Jacobs LK, Fackler MJ, Tsangaris TN, Rudek MA, Higgins MJ, Lange JR, Cheng Z, Slater SA, Jeter SC, Powers P, Briest, Chao C, Yoshizawa C, Sugar E, Espinoza-Delgado I, Sukumar S, Gabrielson E, Davidson NE. Biomarker modulation following short term vorinostat in women with newly-diagnosed primary breast cancer. *Clin Cancer Res*, 19(14):4008-16, 2013. PMID 2371926. PMC3718062
- 257.Moreno-Aspitia A, Hillman DW, Dyer SH, Tenner KS, Gralow J, Kaufman PA, Davidson NE, Lafky JM, Reinholtz MM, Lingle WL, Kutteh LA, Carney WP, Dueck AC, Perez EA. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: Results from

- North Central Cancer Treatment Group adjuvant trial N9831. *Cancer* 119(15): 2675-82, 2013. PMID 23744760
258. Visvanathan K, Hurley P, Bantug, E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L, Garber J, Katapodi M, Kramer B, Marrow M, Parker B, Runowicz C, Vogel VG 3rd, Wade JL, Lippman SMA. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology Clinical Practice Guidelines. *J Clin Oncol*, 31(23): 2942-62, 2013. PMID 23835710
259. Yang L, Zahid M, Liao Y, Rogan EG, Cavalieri EL, Davidson NE, Yager JD, Visvanathan K, Groopman, JD, Kensler TW. Reduced formation of depurinating estrogen-DNA adducts by sulforaphane or KEAP1 disruption in human mammary epithelial MCF-10A cells. *Carcinogenesis*, 34 (11):2587-92, 2013. PMID 23843041. PMC3888356
260. van Londen GJ, Beckjord EB, Dew MA, Cooper KL, Davidson NE, Bovbjerg DH, Donovan HS, Thurston RC, Morse JQ, Nutt S, Rechis R. Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors. *Support Care Cancer* 2014. 22(4):937-45. [Epub ahead of print] PMID 24271937, PMC 3987952, NIHMS 544009
261. Shaw PG, Chaerkady R, Wang T, Vasilatos S, Huang Y, Van Houten B, Pandey A, Davidson NE. Integrated proteomic and metabolic analysis of breast cancer progression. *PLoS One*. 2013. 8(9):e76220. PMID 24086712. PMC3785415
262. Jankowitz RC, McGuire KP, Davidson NE. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer. *Breast*. 22 Suppl 2:S165-70, 2013. PMID: 24074781[PubMed - in process]
263. Dueck AC, Reinholtz MM, Geiger XJ, Tenner K, Ballman K, Jenkins RB, Riehle D, Chen B, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow J, Harris LN, Ingle JN, Lingle WL, Perez EA. Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831. *Clin Cancer Res*.19(20):5798-807, 2013. PMID 23965903. PMC3805021
264. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 *Ann Oncol*. (9):2206-23, 2013. PMID 23917950. PMC3755334.
265. Jankowitz RC, Davidson NE. Adjuvant endocrine therapy for breast cancer: how long is long enough? *Oncology* 27(12):1210-6, 2013. PMID: 24624537
266. Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, Gannon F, Kangaspeska S, Jenlinek J, Issa JP, Richer JK, Elias A, McIllroy M, Young LS, Davidson NE, Schiff R, Li W, Oesterreich S. Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. *Sci Transl Med* 26;6(229):229ra-41, 2014 PMID: 24670685
267. Sikora MJ, Cooper KL, Bahreini A, Luthra S, Wang G, Chandran UR, Davidson NE, Dabbs DJ, Welm AL, Oesterreich S. Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. *Cancer Res*. 1;74(5):1463-74, 2014. PMID 24425047

268. Lee AV, Davidson NE. Breast cancer in 2013: Genomics, drug approval, and optimal treatment duration. *Nat Rev Clin Oncol.* 11(2):71-2, 2014. PMID 24419301
269. Katz TA, Vasilatos SN, Harrington E, Oesterreich S, Davidson NE, Huang Y. Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells. *Breast Cancer Res Treat* 46(1)99-108, 2014. PMID 24924415
270. Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Practice Guidelines focused update. *J Clin Oncol.* 20; 32(21) 2255-69, 2014. PMID 24868023
271. Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Gonzalez-Angulo AM, Kirshner JJ, Krop I, Levinson J, Modi S, Patt DA, Perez EA, Perlmutter J, Winer EP, Lin NU. Recommendation on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology Clinical Practice Guidelines. *J Clin Oncol* 32(19)2100-8, 2014. PMID: 24799487
272. Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, Lin NU, Modi S, Patt DA, Perez EA, Perlmutter J, Ramakrishna N, Winer EP. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol* 32(19) 2078-99, 2014. PMID 24799465
273. Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, Brundage SB, Danso MA, Wilcox M, Smith IE. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guidelines. *J Clin Oncol.* 32(29): 3307-29, 2014. PMID 25185096. [Epub ahead of print]
274. Schneider BP, Li L, Shen F, Miller KD, Radovich M, O'Neill A, Gray RJ, Lane D, Flockhart DA, Jiang G, Wang Z, Lai D, Koller D, Pratt JH, Dang CT, Northfelt D, Perez EA, Shenkier T, Cobleigh M, Smith ML, Railey E, Patridge A, Gralow J, Sparano J, Davidson NE, Foroud T, Sledge GW. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. *Br J Cancer* 111(6):1241-1248, 2014. PMID 25117820
275. Cheng H, Ballman K, Vassilakopoulou M, Dueck AC, Reinholtz MM, Tenner K, Gralow J, Hudis C, Davidson NE, Fountzilas G, McCullough AE, Chen B, Psyrri A, Rimm DL, Perez EA. EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. *Br J Cancer.* 111(6):1065-1071, 2014. PMID 25117817
276. Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtry MM, Garrett-Mayer E, Davidson NE, Hirt K, Berg M, Uram J, Dausse T, Fetting JH, Duus EM, Atay-Rosenthal S, Ye X, Wolff AC, Stearns V, Jaffee EM, Emens LA. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine

- for HER-2+ metastatic breast cancer. *Cancer Immunol Res.* 2(10):949-61, 2014 [Epub ahead of print] PMID 25116755
277. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS. Prognostic value of tumor infiltrating lymphocytes in triple-negative breast cancers from two Phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. *J Clin Oncol* 20; 32(27) 2959-67, 2014 PMID 25071121
278. Katz TA, Huang Y, Davidson NE, Jankowitz RC. Epigenetic reprogramming in breast cancer: From new targets to new therapies. *Ann Med.* 46(6):397-408, 2014. PMID: 250581777
279. Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, Topper MJ, Luo J, Connolly RM, Azad NS, Stearns V, Pardoll DM, Davidson N, Jones PA, Slamon DJ, Baylin SB, Zahnow CA, Ahuja N. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. *Oncotarget* 5(3):587-98, 2014. PMID 24583822. PMC 3996658
280. VanLonden GJ, Donovan HS, Beckjord EB, Cardy AL, Bovbjerg DH, Davidson NE, Morse JQ, Switzer GE, Verdonck-deLeeuw IM, Dew MA. Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms. *Oncol Nurs Forum* 41(6) 660-8, 2014. PMID 25355021
281. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. *J Clin Oncol* 32(33):3744-52, 2014. PMID 25332249
282. Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD; the SOFT Investigators and the International Breast Cancer Study Group. Adjuvant Ovarian suppression in premenopausal breast cancer. *N Eng J Med*, 372(5):436-46, 2015. PMID: 25495490.
283. Connolly RM, Leal JP, Goetz MP, Zhang Z, Zhou XC, Jacobs LK, Mhlanga J, O JH, Carpenter J, Storniolo AM, Watkins S, Fetting JH, Miller RS, Sideras K, Jeter SC, Walsh B, Powers P, Zorzi J, Boughey JC, Davidson NE, Carey LA, Wolff AC, Khouri N, Gabrielson E, Wahl RL, Stearns V. TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer. *J Nucl Med* 56(1):31-37, 2015. PMID 25476537.
284. Lee AV, Oesterreich S, Davidson NE. MCF-7 cells-changing the course of breast cancer research and care for 45 years. *J Natl Cancer Inst* 31;17(7), 2015. PMID 25828948.
285. Reeder A, Attar M, Nazario L, Bathula C, Zhang A, Hochbaum D, Roy E, Cooper KL, Oesterreich S, Davidson NE, Neumann CA, Flint MS. Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage. *Br J Cancer.* 28:112(9): 1461-70, 2015. PMID 25880007.

- 286.Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thurlimann B, Seen HJ; Panel members. Tailoring therapies-improving the management of early breast cancer: St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. *Ann Oncol* 26:153-46, 2015. PMID 25939896.
- 287.Willis S, De P, Dey N, Long B, Young B, Sparano JA, Wang V, Davidson NE, Leyland-Jones BR. Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. *Meta Gene*. 15;4:129-41, 2015. PMID 26005638. PMCID 4438509.
- 288.Sparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Long-term follow-up of the E1199 Phase III trial evaluating the role of taxane and schedule in operable breast cancer. *J Clin Oncol*. 20;33(21):2353-60, 2015. PMID 26077235.
- 289.Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Schilsky RL. American Society of Clinical Oncology statement: A conceptual framework to assess the value of cancer treatment options. *J Clin Oncol* 10;33(23):2563-77, 2015. PMID 26077235.
- 290.Nayak SR, Harrington E, Hartmaier R, Chen J, Pathiraja TN, Cooper KL, Fine JL, Sanflippo J, Davidson NE, Lee AV, Dabbs D, Oesterreich S. A role for histone H2B variants in endocrine-resistant breast cancer. *Horm Cancer*, 6(5-6) 214-24, 015. PMID 26113056.
- 291.Schneider BP, Li L, Radovich M, Shen F, Miller C, Flockhart DA, Jiang G, Vance GH, Gardner L, Vatta M, Bai C, Lai D, Koller D, Zhao F, O'Neill A, Smith ML, Railey E, White C, Partridge A, Sparano JA, Davidson NE, Foroud T, Sledge GW. Genome-wide association studies for taxane-induced peripheral neuropathy (TIPN) in ECOG-5103 and ECOT-1199. *Clin Cancer Res*. 21:5082-1 2015. PMID 26138065.
- 292.Katz TA, Liao S, Palmieri VJ, Dearth RK, Pathiraja TN, Hou Z, Shaw P, Small S, Davidson NE, Peters DG, Tseng G, Oesterreich S, Lee AV. Targeted DNA methylation screen in the mouse mammary genome reveals a parity-induced hypermethylation of IGF 1R which persists long after parturition. *Cancer Prev Res*, 8(10):1000-9, 2015. PMID 26290394.
- 293.Brown DD, Dabbs DJ, Lee AV, McGuire KP, Ahrendt GM, Bhargava R, Davidson NE, Brufsky AM, Johnson RR, Oesterreich S, McAuliffe PF. Developing in vitro models of human ductal carcinoma in situ from primary tissue explants. *Breast Cancer Res Treat*. 153(2):311-21, 2015. PMID 26283301.
- 294.Mathew A, Davidson NE. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. *Breast*. Nov;24 Suppl 2:S120-5. 2015. PMID 26255743.
- 295.Liao S, Hartmaier RJ, McGuire KP, Puhalla SL, Luthra S, Chandran UR, Ma T, Bhargava R, Modugno F, Davidson NE, Benz S, Lee AV, Tseng GC, Oesterreich S. The molecular landscape of premenopausal breast cancer. *Breast Cancer Res*. 17:104. 2015. PMID 26251034.
- 296.Schneider BP, Li L, Radovich M, Shen F, Miller C, Flockhart DA, Jiang G, Vance GH, Gardner L, Vatta M, Bai C, Lai D, Koller D, Zhao F, O'Neill A, Smith ML, Railey E, White

- C, Patridge A, Sparano JA, Davidson NE, Foroud T, Sledge GW. Genome-wide association studies for taxane-induced peripheral neuropathy (TIPN) in ECOG-5103 and ECOG-1199. *Clin Cancer Res.* 2015 [Epub ahead of print].
297. Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE. Surgical excision without radiation for ductal carcinoma in situ breast: 12-year results from the ECOG-ACRIN E5194 study. *J Clin Oncol* 2015 [Epub ahead of print].
298. Perez EA, Baehner FL, Butler SM, Thompson EA, Dueck AC, Jamshidian F, Cherbabaz D, Yoshizawa C, Shak S, Kaufman PA, Davidson NE, Gralow J, Asmann YW, Ballman KV. The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. *Breast Cancer Res* 1:17(1):133, 2015. PMID 26429296.
299. Wang P, Bahreini A, Gyanchandani R, Lucas P, Hartmaier RJ, Watters RJ, Jonnalagadda AR, Trejo Bitta HE, Berg A, Hamilton RL, Kurland BF, Weiss K, Mathew A, Leone JP, Davidson NE, Nikiforova MN, Brufsky AM, Ambros TF, Stern AM, Puhalla S, Lee AW, Oesterreich S. Sensitive detection of mono-and polyclonal ESR1 mutations in primary tumors, metastatic lesions and cell free DNA of breast cancer patients. *Clin Cancer Res*, 2015 [Epub ahead of print].

Editorials

1. Davidson NE and Lippman ME. Combined therapy in advanced breast cancer. *Eur. J. Cancer Clin. Oncol.* 21:1123-6, 1985
2. Davidson NE and Lippman ME. Stimulation of breast cancer with estrogens: how much clinical value? *Eur. J. Cancer Clin. Oncol.* 23:897-900, 1987
3. Davidson NE. Out of the courtroom and into the clinic. *J. Clin. Oncol.* 10:517-9, 1992
4. Davidson NE. Tamoxifen - panacea or Pandora's box? *N. Engl. J. Med.* 326:885-6, 1992
5. Davidson NE. Hormone replacement therapy: Breast vs heart vs bone. *N. Engl. J. Med.* 332:1638-9, 1995
6. Davidson NE. and Yager JD. Pesticides and breast cancer: fact or fad? *J. Natl. Cancer Inst.* 89:17434, 1997
7. Nass SJ, Hahm HA and Davidson NE. Breast cancer biology blossoms in the clinic. *Nature Medicine.* 4:761, 1998
8. Davidson NE. Combined endocrine therapy for breast cancer - new life for an old idea? *J. Natl. Cancer Inst.* 92:859-60, 2000
9. Davidson NE and Levine ME. Breast cancer consensus meetings: vive la difference? *J Clin Oncol.* 20:1719-20, 2002
10. Davidson NE and Helzlsouer KJ. Good news about oral contraceptives. *N. Engl. J. Med.* 346:2078-9, 2002
11. Park BH and Davidson NE. Estrogen receptor status, cell cycling and paclitaxel looking for a "hormone"-ious explanation. *Cancer Biology & Therapy* 3:468-9, 2004

12. Stearns V and Davidson NE. Déjà vu for breast cancer two? *J Natl Cancer Inst* 96: 497-499, 2004
13. Davidson NE and Morrow M. Sometimes a great notion--an assessment of neoadjuvant systemic therapy for breast cancer. *J Natl Cancer Inst.* 97:159-61, 2005
14. Davidson NE and Sukumar S. Of Snail, mice and women. *Cancer Cell.* 8:173-4, 2005
15. Kominsky SL and Davidson NE. A “bone” fide predictor of metastasis? Predicting breast cancer metastasis to bone. *J Clin Oncol,* 24:2227-9, 2006
16. Zhou Q and Davidson NE. Silencing estrogen receptor alpha in breast cancer cells. *Cancer Biol Ther.* 5:848-9, 2006
17. Wolff AC and Davidson NE. Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer, *J Clin Oncol,* 24:4949-4951, 2006
18. Visvanathan K, Sukumar S and Davidson, NE Epigenetic biomarkers and breast cancer: cause for optimism, *Clinical Cancer Research* 12:6591-92, 2006
19. Stebbing J, Stearns V, and Davidson NE. Role of CYP2D6 testing in selection of endocrine therapy for breast cancer. *Pharmacogenomics.* 8:1-3, 2007
20. Davidson, NE. The maturation of medical oncology. *Lancet Oncol.* 8:457-8, 2007
21. Park BH and Davidson NE. PI3 kinase activation and response to trastuzumab therapy: What's neu with Herceptin resistance? *Cancer Cell* 4:297-9, 2007
22. Davidson NE. In memoriam. Martin D. Abeloff, *J Clin Oncol* 26:1573-4, 2008
23. Chivukula M, Brufsky A., Davidson NE. Small beginnings: do they matter? The importance of lymphovascular invasion in early breast cancer. *J Natl Cancer Inst.* 101(10) 698-9, 2009
24. Rastogi P, Davidson NE. Trastuzumab as single agent therapy for HER2-positive metastatic breast cancer. *Onkologie* 33:420-1, 2010
25. Oesterreich, S, Lee AV, Davidson NE. Is it time to reSET the standard for estrogen receptor testing in breast cancer? *J Clin Oncol* 28:4101-3, 2010
26. Davidson, NE, Kensler TW. “MAPping” the course of chemoprevention in breast cancer. *N Engl J Med* 364(25):2463-4, 2011. PMID 21639807
27. Puhalla S, Jankowitz RC, Davidson NE. Adjuvant endocrine therapy for breast cancer: don't ditch the switch! *J Natl Cancer Inst* 103:1280-2, 2011. PMID 21859987
28. Bhargava R, Brufsky AM, Davidson NE. Prognostic/predictive immunohistochemistry assays for estrogen receptor-positive breast cancer: back to the future? *J Clin Onc* 30(36):4451-3, 2012. PMID 23045595
29. McAuliffe PF, Danoff S, Shapiro SD, Davidson NE. Treatment for breast cancer: is time really of the essence? *J Natl Cancer Inst* 105(2):8-2, 2012. PMID 23264682
30. Sharma D, Davidson NE. Obesity and breast cancer: a multipartite connection. *J Mammary Gland Biol Neoplasia.* 18(3-4):253-5, 2013. PMID:24190309
31. Oesterreich S, Brufsky AM, Davidson NE. Using mice to treat (wo)men: mining genetic changes in patient xenografts to attack breast cancer. *Cell Rep.* 4(6):1061-2, 2013 PMID:24075202[PubMed - in process]
32. Oesterreich S, Davidson NE. The search for ESR1 mutations in breast cancer. *Nat Genet.* 45(12):1415-6, 2013. PMID: 24270445
33. Jankowitz RC, Puhalla S, Davidson NE. Should we embrace or ablate our urge to (ovarian) suppress? *J Clin Oncol.* 32(35): 3920-2, 2014. PMID: 25366692.

34. Mathew A, Brufsky AM, Davidson NE. Can circulating tumor cells predict resistance in metastatic breast cancer: Clin Cancer Res 2:2967, 2014. PMID 25645864
35. Davidson NE, Rimm DL. Expertise vs evidence in assessment of breast biopsies: an atypical science. JAMA 17:313(11):1109-10, 2015. PMID 25781438

Articles in the Lay Press

1. Davidson NE. Is hormone replacement a risk? Scientific American. 275:101, 1996.
2. Davidson NE. Hormone replacement therapy in perspective; Medical and Health Annual, Encyclopedia Britannica, Inc., Chicago, IL pp. 361-6, 1997.

Book Reviews

1. Davidson NE. Molecular Endocrinology and Steroid Hormone Action: Progress in Clinical and Biologic Research, Volume 322, J Natl Cancer Inst. 82:1150, 1990.
2. Davidson NE. The Breast: Comprehensive Management of Benign and Malignant Diseases. J. Natl. Cancer Inst. 84:806, 1992.
3. Davidson NE. Diseases of the Breast. J Natl Cancer Inst. 89:85, 1997.
4. Davidson NE. Emperor of All Maladies: A Biography of Cancer. Lancet 377:801, 2011.

Books Edited

The Breast Comprehensive Management of Benign and Malignant Disease (Second edition),
Edited by Bland KI, Copeland EM, III, Davidson NE, Mendenhall NP, Page DL, and
Wilkinson EJ. W.B. Saunders Company, Philadelphia, PA, 1998.

The Breast Comprehensive Management of Benign and Malignant Disorders (Third edition)
Edited by Bland KI, Copeland, III, EM, Davidson NE, Page DL, Recht A, and Unst MM.
Saunders, Philadelphia, PA, 2004.

Book Chapters

1. Lippman ME, Dickson RB, Gelmann EP, Kasid A, Bates S, Knabbe C, Swain SM, McManaway M, Wilding G, Davidson N, Huff K, and Bronzert D. Mechanisms of growth regulation of human breast cancer. In: Advances in Gene Technology. Molecular Biology of the Endocrine System. Ed. by Paett, D., Ahmeod, F., Beach, S., and Whelon, W.J. ISCU Short Reports, Vol. 4, 1986, p. 254-257.
2. Davidson NE and Lippman ME. Adjuvant therapy for breast cancer. In Diagnosis and Management of Breast Cancer, Lippman, ME, Lichter, AS, and Danforth, DN (eds). W.B. Saunders and Co., Philadelphia, 1988, pp 348-374.
3. Davidson NE and Lippman ME. Treatment of metastatic breast cancer. In Diagnosis and Management of Breast Cancer, Lippman, ME, Lichter, AS, and Danforth, DN (eds). W.B. Saunders and Co., Philadelphia, 1988, pp 375-406.
4. Dickson RB, Knabbe C, Bates SE, Huff K, Davidson NE, Bronzert D, Swain S, Valverius E, Gelmann EP, and Lippman ME. Growth factors, receptors, and oncogenes in breast cancer. In: Current Perspectives in Breast Cancer, Ed by I Mittra, Mata & McGraw Hill Publishing Co. Ltd, Bombay, India, 1988, pp 73-80.

5. Kensler TW, Davidson NE, Egner PA, Guyton KZ, Groopman JD, Liu Y-L and Roebuck BD. Mechanisms of chemoprotection against aflatoxin-induced hepatocarcinogenesis by oltipraz. In: Anticarcinogenesis & Radiation Protection 2, Ed by Nygaard OF and Upton AC, Plenum, New York, 1991, pp 315-322.
6. Antman K, Bearman SI, Davidson N, deVries E, Gianni AM, Gisselbrecht C, Kaiser H, Lazarus HM, Livingston RB, Maraninchi D, McElwain TJ, Ogawa M, Peters W, Rosti G, Slease RB, Spitzer G, Tajima T, Vaughan WP and Williams S. Dose intensive therapy in breast cancer: current status. In: New Strategies in Bone Marrow Transplantation. Ed by Gale, RP and Champlin, RE. Wiley-Liss, Inc. New York, 1991, pp 423-436.
7. Davidson NE and Abeloff MD. Adjuvant chemotherapy for axillary lymph node-positive breast cancer. In: Adjuvant Therapy of Breast Cancer. Ed by Henderson, IC, Kluwer Academic Publishers, Norwell, MA, 1992, pp 115-145.
8. Kensler TW, Davidson NE, Egner PA, Guyton KZ, Groopman JD, Curphy TJ, Liu Y-L and Roebuck BD. Chemoprotection against aflatoxin-induced hepatocarcinogenesis by dithiolethiones, In: Mycotoxins, Cancer, and Health. Ed by Bray, G. and Ryan, D.LSU Press, Baton Rouge, LA, 1991, pp 238-252.
9. Davidson NE and Ableoff MD. Adjuvant systemic therapy for axillary node-negative breast cancer. In: Cancer Principles and Practice of Oncology PPO Update, Ed. by DeVita, Jr. VT, Hellman S, and Rosenberg SA. JB Lippincott, Philadelphia, 1992, Vol. 6, Number 7, pp 1-13.
10. Kensler TW, Davidson NE and Guyton KZ. Antioxidants and oncogenesis: roles in cancer causation and prevention. In: Atmospheric Oxidation and Antioxidants. Ed. by Scott G. Elsevier, Amsterdam, 1992, pp. 333-354.
11. Davidson NE. Breast cancer - molecular approaches and cell kinetics in assessing risk, In: Current Therapy in Oncology, Ed. by Niederhuber J, BC Decker Inc., Philadelphia, 1993, pp 304-308.
12. Kensler TW, Davidson NE, Groopman JD, Roebuck BD, Prochaska HJ and Talalay P. Chemoprotection by inducers of electrophile detoxication enzymes. In: Antimutagenesis and Anticarcinogenesis Mechanisms III, Ed. by Bronzetti G, DeFlora S, Waters MD, Hayatsu H and Shankel DE, Plenum Press, 1993, pp 127-136.
13. Davidson NE and Kennedy JM. Protein kinase C and breast cancer. In: Mammary Tumor Cell Cycle, Differentiation and Metastasis. Eds by Dickson RB and Lippman ME, Kluwer Academic Publishers, Boston, 1996, pp 91-105.
14. McCloskey DE, Armstrong DK, Jackisch C and Davidson NE. Programmed cell death in human breast cancer cells. In: Recent Progress in Hormone Research, Vol 51, Ed. by Conn, PM. The Endocrine Society, Baltimore, MD, 1996, pp 493-508.
15. Couzi RJ and Davidson NE. Breast cancer. In: Women's Health in Primary Care, Ed. by Rosenfeld JA, Williams & Wilkins, Baltimore, MD, 1996, pp 683-702.
16. Denmeade SR, McCloskey DE, Joseph IJK, Hahm HA, Isaacs JT and Davidson NE. Apoptosis in hormone - responsive malignancies. In: Advances in Pharmacology, Ed. By Kaufmann, S.H., Academic Press, Inc., San Diego, 1997, pp 553-583.
17. Ferguson AT, Lapidus RG and Davidson NE. The regulation of estrogen receptor expression and function in breast cancer. In: Biological and Hormonal Therapies of

- Cancer. Ed. By Foon KA and Muss, HB, Kluwer Academic Publishers, Boston, 1998, pp 255-278.
18. Davidson NE. Treatment of breast cancer with autologous bone marrow transplantation. In: Current Surgical Therapy, Ed. by Cameron, J.L. Mosby, Inc., St. Louis, 1998, pp 640-643.
 19. Davidson NE and Kennedy MJ. Dose-intensive chemotherapy for breast cancer. In: Diseases of the Breast Updates, Ed. by Harris, J.R. and Lippman, M.E. Lippincott-Raven, 1998, vol. 2, No. 3, pp 1-10.
 20. Davidson NE and Valagussa P. Summary. In: Adjuvant Therapy of Primary Breast Cancer VI, Ed by Senn H-J, Gelber R, Goldhirsch A and Thurliman B. Springer-Verlag, Berlin, 1998, pp 368-370.
 21. Davidson NE, Hahm HA and Armstrong DK. Apoptosis and breast cancer. In: Cancer Chemotherapy and Apoptosis, Ed. by Hickman, J.A. and Dive, C., Humana Press, 1999, pp 291-303.
 22. Davidson NE. Breast Cancer. In: Scientific American Medicine, Ed. by Dale DC and Federman, DD, Scientific American, Inc., New York City, 1999, 12 ONCO VII 1-13.
 23. Wolff AC, Lange JR and Davidson NE. Occult primary cancer with axillary node metastasis. In: Advanced Therapy of Breast Disease Ed. by Singletary, S.E. and Robb, G.L. BC Decker Inc., 2000, pp 191-195.
 24. Emens LA, Davidson NE. Posoperative Endocrine Therapy in Invasive Breast Cancer, Steven T Rosen MD Series Editor. In: Cancer Treatment and Research, Ed by Monica Castiglione, Martine J. Piccart. Springer, 2009 pp 139-161.
 25. Davidson NE, Kennedy MJ and Armstrong DK. Dose-intensive chemotherapy. In: Diseases of the Breast, Ed. by Harris JR, Lippman ME, Morrow M and Osborne CK. Lippincott Williams & Wilkins, Philadelphia. 2000, pp 633-644.
 26. Kensler TW, Davidson NE, Groopman JD and Muñoz A. Biomarkers and surrogacy: relevance to chemoprevention. In: Biomarkers in Cancer Chemoprevention. Ed. by Miller AB, Bartsch H, Boffetta P, Dragsted L and Vainio H. IARC Scientific, International Agency for Research on Cancer. Lyon, 2001, pp 27-47.
 27. Brewster A and Davidson N. Breast cancer screening. In: Handbook of Women's Health: An evidence-based approach. Ed. By Rosenfeld, J.A. Cambridge University Press, N.Y., N.Y., 2001, pp 383-398.
 28. Wolff AC, Stearns V and Davidson NE. Adjuvant systemic therapy of breast cancer. In: The Breast Comprehensive Management of Benign and Malignant Disorders. Ed. By Bland KI, Copeland III EM, Davidson NE, Page DL, Recht A, and Unst MM. Saunders, Philadelphia, PA, 2004, pp 1189-1232.
 29. Stearns V and Davidson NE. Adjuvant chemotherapy and chemoendocrine therapy for primary breast cancer. IN: Diseases of the Breast. Ed. By Harris JR, Lippman ME, Morrow M and Osborne CK. Lippincott Williams & Wilkins, Philadelphia, PA., 2004,pp 893-920.
 30. Davidson NE and Osborne CK. Adjuvant systemic therapy treatment guidelines. IN: Diseases of the Breast. Ed. By Harris JR, Lippman ME, Morrow M and Osborne CK. Lippincott, William & Wilkins, Philadelphia, PA., 2004, pp 945-950.

31. Carraway H and Davidson NE. Adjuvant hormonal therapy in premenopausal women. VII. Systemic management of stage I and II breast cancer. In: Advanced Therapy of Breast Disease. Second Edition. Ed. By Singletary, E., Robb, Hortobagyi, G. BC Decker Inc., Hamilton, Ontario, 2004, pp 451-458.
32. Davidson NE. Breast Cancer IN: WebMD 12 VII Breast Cancer 1-15, 2004.
33. Prowell T, Davidson N. Metastatic breast cancer: Tailored endocrine therapy for premenopausal women. IN: Breast Cancer Management in the Era of Molecular Medicine—Towards Tailored Approaches. Ed. By Piccart M, Wood W, Hung M-C, Solin L, Cardoso F. Springer-Verlag, in press.
34. Visvanathan K and Davidson NE. Adjuvant endocrine therapy: controversies and perspectives. IN: Textbook of Breast Cancer: A Clinical Guide to Therapy, Third Edition. Ed. By Bonadonna G, Hortobagyi GN, Valagussa P. Taylor & Francis Group, 2006, pp 205-223.
35. Huang Y and Davidson NE. Breast cancer. IN: Principles of Molecular Medicine, Second Edition. Ed. By Runge, M.S. and Patterson, C. Humana Press, Inc., 2006, pp 728-735.
36. Stearns V, Zhou Q, and Davidson NE. Epigenetic regulation as a new target for breast cancer therapy. IN: Breast Cancer: Translational Therapeutic Strategies. Ed. by Lyman GH, Burstein H. Informa Healthcare USA, Inc. New York City, 2007, pp 285-295.
37. Davidson NE. Breast Cancer IN: WebMD 12 VII Breast Cancer 1-16, 2007.
38. Bao T and Davidson NE. Gene expression profiling of breast cancer. IN Advances in Surgery Volume 42 Ed. by Cameron JL, 2008, pp 249-60.
39. Stearns V, Davidson NE. Adjuvant Systemic Therapy: Chemoendocrine IN: Diseases of the Breast. Ed. by Harris JR, Lippman ME, Morrow M and Osborne CK. Lippincott, Williams & Wilkins, Philadelphia, PA 2009, pp 645-656.
40. Davidson NE, Winer EP, Osborne CK. Guidelines for Adjuvant Systemic Therapy IN: Diseases of the Breast. Ed. By Harris JR, Lippman ME, Morrow M and Osborne CK Lippincott, William & Wilkins, Philadelphia, PA., 2009, pp 711-713.
41. Emens LA, Davidson NE, Postoperative Endocrine Therapy for Invasive Breast Cancer IN: Adjuvant Therapy for Breast Cancer. Ed by Castiglione M, Piccart MJ. Springer, 2009, pp 139-161.
42. Reeder, JG, Lembersky BC, Davidson NE. Advances in Adjuvant and Neoadjuvant Therapy for Breast Cancer. IN: Current Surgical Therapy 10th Edition, Ed. by Cameron JL, Cameron AM. Elsevier Saunders, 2011, pp 547-552.
43. Davidson, NE. Breast Cancer and Benign Breast Disorders IN: Goldman's Cecil Medicine 24th Edition. Ed. by Goldman L, Schafer AI. , Elsevier Saunders, 2012, pp 1309-1316.
44. Jankowitz RC, Davidson NE. Adjuvant Hormonal Therapy in Premenopausal Women IN: Advanced Therapy of Breast Disease, Third Edition. Ed. by Babiera GV, Skoracki RJ, Esteva FJ, Peoples Medical Publishing, 2012, pp 799-811.
45. Wolff AC, Domchek SM, Davidson NE, Sacchini V, McCormick. Cancer of the Breast. IN: Abeloff's Clinical Oncology, 5th Edition. Ed. by Niederhuber JE, Armitage JO,

- Doroshow JH, Kastan MB, Tepper JE., Elsevier Churchill Livingstone, 2013. pp 1630-1692.
46. Stearns V, Davidson NE. Adjuvant Systemic Therapy: Chemoendocrine IN: Diseases of the Breast 5th Edition. Ed. by Harris JR, Lippman ME, Morrow M and Osborne CK, Lippincott Williams & Wilkins, 2014. pp 649-666.
 47. Multiple authors including Davidson NE. The Health Consequences of Smoking—50 Years of Progress. A Report of the Surgeon General. US Department of Health and Human Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014, pp 1-943.
 48. Jankowitz RC, Davidson NE. Breast Cancer IN: Hematology-Oncology Therapy – Second Edition, Ed. by Boyiadzis MM, Frame JN, Kohler DR, Fojo T, McGraw Hill Education, 2014, pp 88-190.
 49. Lee AV, Oesterreich S, Davidson NE. The Molecular Biology of Breast Cancer. IN: The Molecular Basis of Cancer 4th Edition. Ed. by Mendelsohn J, Gray JW, Howley PM, Israel MA, Thompson CB, Elsevier Saunders, 2015, pp 523-30.

Professional activities

TEACHING:

1988-2005	Lecturer, Pathophysiology Course for 2 nd Year Medical Students
1991	Medical Student Advisor
1996-2009	Lecturer, Fundamentals of Clinical Oncology for Public Health Practitioners
1997-2009	Lecturer, Topics in Molecular Endocrinology, School of Public Health
2004-2009	Lecturer, Pathophysiology of Disease, Cellular and Molecular Medicine
2009-present	Lecturer, Cancer Biology and Therapy

Mentoring

<u>Postdoctoral Fellows – Laboratory</u>	<u>Current Position</u>
1988-1990 M. John Kennedy, MD	Consultant, St. James Hospital, Dublin, Ireland
1989-1992 Deborah K. Armstrong, MD	Professor of Oncology, Johns Hopkins
1991-1993 Yvonne L. Ottaviano, MD	Private Practice, Baltimore, MD
1993-1996 Diane McCloskey, PhD	Associate Professor of Cellular & Molecular Physiology, Penn State, Hershey, PA
1993-1997 Rena Lapidus, PhD	Assistant Professor, University of Maryland
1993-1998 Anne Ferguson, PhD	Non-profits, San Francisco, CA
1994-1995 Christian Jackisch, MD	Chief, Clinic for Gynecology and Obstetrics, Klinikum Offenbach, Offenbach, Germany
1996-1999 Hillary Hahm, MD, PhD	Private Practice, Atlanta, GA
1997-1999 Sharyl Nass, PhD	Policy Analyst, Institute of Medicine, Washington, DC
1998-2001 Xiaowei Yang, MD, PhD	Staff Scientist, National Cancer Institute
1999-2001 Valerie Dunn, MD	Private Practice, Rochester, NY

2000-2001	Lan Yan, MD, PhD	Staff Scientist, Amgen, Thousand Oaks, CA
2001-2006	Yi Huang, MD, PhD	Assistant Professor, University of Pittsburgh, Pittsburgh, PA
2001-2004	Judith C. Keen, PhD	National Breast Cancer Coalition, Washington DC
2002-2003	Dipali Sharma, PhD	Associate Professor of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
2004-2006	Qun Zhou, MD, PhD	Associate Professor of Biochemistry and Molecular Biology, University of Maryland Medical School
2005-2006	Allison Tracy, PhD	Lecturer of Chemistry and Biochemistry, UMBC
2006-2009	Qingsong Zhu, PhD	Chief Operating Officer, In Silico Medicine, Inc.
2006-2009	Madhavi Billam, PhD	Senior Toxicologist, L’Oreal USA & RI
2011-2013	Tiffany Katz, PhD	Postdoctoral Associate, University of Pittsburgh
2014-present	Nilgun Tasdemir, PhD	Postdoctoral Fellow, University of Pittsburgh

Doctoral Students

2000-2005	Julie Blum, PhD	Clinical Content Manager, MED-IQ
2001-2005	Allison Pledgie, PhD	Senior Lecturer in Chemistry and Biochemistry at University of Maryland Baltimore County (UMBC)
2004-2010	Abigail Witt, PhD	Postdoctoral Fellow, University of Miami School of Medicine
2005-2010	Talmesha Richards, PhD	Chief Academic and Diversity Officer at STEMconnector
2006-2010	Patrick Shaw, PhD	Chief, Pathogen Detection Lab. USA Public Health Command Region-Pacific Camp Zama, Japan

Graduate Training Programs

1997-2011	Biochemistry and Molecular Biology, Hopkins Bloomberg School of Public Health (adjunct 2009-2011)
1999-2013	Cellular and Molecular Medicine, Hopkins School of Medicine (adjunct 2009-2013)

RESEARCH:

1. CURRENT GRANT SUPPORT:

Grants Awarded as Principal Investigator

2009-	NIH P30CA047904. Cancer Center Support Grant
1998-	Breast Cancer Research Foundation
2009-2016	TBCRC Translational Breast Cancer Research Consortium and the Komen Foundation.
2009-2016	TBCRC Translational Breast Cancer Research Consortium and the Avon Foundation.
2010-2016	North American Breast Cancer Group/Breast International Group Collaboration and the Breast Cancer Research Foundation

2014-2017 Department of Defense, W81XWH-14-1-0238, Targeting Histone Abnormality in Triple-Negative Breast Cancer

1a. PRIOR GRANT SUPPORT

Grants Awarded as Principal Investigator

- 1986-1987 American Society of Clinical Oncology Young Investigator Award, "Isolation of estrogen-induced genes from human breast cancer."
- 1987-1988 American Cancer Society Institutional Grant, "The relationship between epidermal growth factor receptor and estrogen receptor in breast cancer."
- 1987-1989 American Cancer Society Maryland Division. "The role of epidermal growth factor and its receptor in breast cancer."
- 1987-1988 Susan G. Komen Foundation. "The role of epidermal growth factor and its receptor in human breast cancer."
- 1988-1991 American Cancer Society Clinical Oncology Career Development Award.
- 1989-1995 NIH Grant R29 CA 49634. "Epidermal growth factor receptor in human breast cancer."
- 1989-1990 Phil N. Allen Charitable Trust Grant. "Novel approaches to hormone-unresponsive breast cancers."
- 1989-1990 Merck Clinician Scientist Award, Johns Hopkins University School of Medicine.
- 1990-1991 Johns Hopkins University School of Medicine Institutional Research Grant, "Elimination of breast cancer cells from human bone marrow by counterflow centrifugal elutriation".
- 1991-1993 Susan G. Komen Breast Cancer Foundation Fellowship.
- 1991-1992 Mildred Mindell Cancer Foundation, Inc. "Incidence of p53 mutations in the germ-line of young women with breast cancer".
- 1992-1994 NIH Grant R01 CA57545. "Programmed cell death in human breast cancer cells"
- 1992-1994 NIH Grant P30 CA06973 pilot. "DNA methylation and estrogen receptor expression in human breast cancer cells"
- 1995-1997 Susan G. Komen Breast Cancer Foundation Fellowship.
- 1994-1998 NIH Grant R21 CA/ES 66204 "Development of a breast cancer program at Johns Hopkins".
- 1994-1995 NIH Grant 5P50 CA-58236 pilot. "Effects of polyamine analogues on growth of human prostatic cancer cells"
- 1995-1999 NIH Grant 1 U01 CA66084. "New therapeutic approaches for breast cancer".
- 1995-1998 American Cancer Society BE-237 "Methylation of steroid receptors in human breast cancer".
- 1996-1997 Susan G. Komen Foundation, "Functional significance of DNA methylation of estrogen receptor in breast cancer."
- 1998-2004 NIH Grant R01 CA78352 "DNA methylation as a determinant of hormone resistant breast cancer."
- 1999-2003 DOD-USAMRDC DAMD 17-99-1-9242. "Therapeutic and chemopreventive actions of a novel polyamine analog against breast cancer"
- 1998-1999 NIH Grant P50 pilot. "Activity of a novel polyamine analog against breast cancer"

2001-2009	Avon Foundation
2001-2005	Susan G. Komen Foundation Postdoctoral Fellowship
2003-2005	Susan G. Komen Foundation Predoctoral Fellowship
2000-2009	American Breast Cancer Foundation
2006-2008	Susan G. Komen Foundation, BCTR 65706, "Polyamine analogues as novel anti-estrogen receptor alpha agents"
2007-2009	Lee Jeans Translational Breast Cancer Research Program (with Entertainment Industry Foundation)
2008-2011	Susan G. Komen for the Cure, KG080923, Inhibition of lysine specific demethylase 1 (LSD1) as a strategy for re-expression of epigenetically silenced genes in breast cancer Robert Casero, Jr. and Nancy E. Davidson (Co-PIs)
2000-2013	NIH P50 CA88843. SPORE in Breast Cancer (co-PI of University of Pittsburgh site 2009-2012)
2011-2013	Gynecologic Center of Excellence. Henry M. Jackson Foundation
2009-2013	Stand up to Cancer (AACR). Bringing epigenetic therapy to the forefront of cancer. (Dream Team Principal with Stephen Baylin and Peter Jones)

2. Seminars and Invited Lectureships

Invited Seminars

1985	Grand Rounds, Washington Veterans Administration Hospital, Washington, DC
1986	Medical Grand Rounds, Johns Hopkins Medical Institutions, Baltimore, MD Symposium on Breast Cancer, Millville Hospital, Vineland, NJ Department of Hematology-Oncology, University of Missouri, Kansas City, MO Kansas City Round Table of Hematology/Oncology, Kansas City, MO American Association of Osteopathic Internists, Washington, DC Cincinnati Cancer Conference V, Cincinnati, OH Advances in Oncology, Cherry Hill, NJ
1987	13th Annual Symposium on Diagnosis and Treatment of Neoplastic Disorders Course, Johns Hopkins Medical Institutions, MD Breast Cancer Session, Eastern Cooperative Oncology Group, Clearwater, FL
1988	Early Breast Cancer Conference, Memorial Hospital, Colorado Springs, CO Grand Rounds, Liberty Medical Center, Baltimore, MD Medical Grand Rounds, Johns Hopkins Medical Institutions, Baltimore, MD Annual Hematology/Oncology Conference, The Medical Center of Delaware, Wilmington, DE Department of Medicine Professors Rounds, Johns Hopkins Medical Institutions, Baltimore, MD Medical Residents Journal Club, Johns Hopkins Medical Institutions, Baltimore, MD Plastic Surgery Grand Rounds, Johns Hopkins Medical Institutions, Baltimore, MD

- 1989 Department of Medicine Bench to Bedside, Johns Hopkins Medical Institutions, Baltimore, MD
Twelfth Annual Symposium on Current Concepts in Medicine and Surgery, Peninsula General Hospital, Salisbury, MD
Topics in Internal Medicine Course, Johns Hopkins Medical Institutions, Baltimore, MD
15th Annual Symposium on Diagnosis and Treatment of Neoplastic Disorders, Johns Hopkins Medical Institutions, Baltimore, MD
Eleventh Annual Cancer Symposium Selected Topics in Oncology, Raleigh, NC
Plastic Surgery Grand Rounds, Johns Hopkins Medical Institutions, Baltimore, MD
St. George's Society, Johns Hopkins Medical Institutions, Baltimore, MD
Hematology-Oncology Division Seminar, Indiana University School of Medicine, Indianapolis, IN
- 1990 Grand Rounds, St. Agnes Hospital, Baltimore, MD
Department of Medicine Bench to Bedside, Johns Hopkins Medical Institutions, Baltimore, MD
American Cancer Society, Maryland Division, Baltimore, MD
Medical Grand Rounds, Johns Hopkins Medical Institutions, Baltimore, MD
16th Annual Symposium on Diagnosis and Treatment of Neoplastic Disorders, Johns Hopkins Medical Institutions, Baltimore, MD
NCI Strategy Meeting on High Dose Chemotherapy in Breast Cancer, National Cancer Institute, Bethesda, MD
Hematology-Oncology Division Seminar, University of Maryland School of Medicine, Baltimore, MD
- 1991 Hematology-Oncology Conference, Chester Hospital, West Chester, PA
Department of Medicine Professors Rounds, Johns Hopkins Medical Institutions, Baltimore, MD
Symposium on Early Breast Cancer, Montgomery General Hospital, Olney, MD
Hematology-Oncology Division Seminar, Northwestern University School of Medicine, Chicago, IL
Pennsylvania Oncology Society, Gettysburg, PA
Susan G. Komen Foundation Scientific Symposium, University of Texas - Southwestern Medical School, Dallas, TX
- 1992 Breast Cancer Symposium, Crozer-Chester Hospital, Upland, PA
Hematology-Oncology Grand Rounds, University of Maryland School of Medicine, Baltimore, MD
Department of Medicine Ambulatory Care Rounds, Johns Hopkins Medical Institutes, Baltimore, MD
Staff Conference, Roswell Park Cancer Institute, Buffalo, NY
Tumor Board, Anne Arundel Hospital, Annapolis, MD
18th Annual Symposium on the Diagnosis and Treatment of Neoplastic Disorders, Johns

Hopkins Medical Institutions, Baltimore, MD
American Cancer Society, Teaneck, NJ
Australia - New Zealand Breast Cancer Trials Group, Surfers Paradise, Australia
Laboratory of Biologic Chemistry, National Cancer Institute, Bethesda, MD
Lederle Advisory Board, New York City, NY
Gordon Conference on Cancer, Newport, RI
American Society of Clinical Pathologists, Las Vegas, NV
The Cancer Center at Fairfax Hospital, Fairfax, VA
American Fertility Society, New Orleans, LA
Visiting Professor, Department of Medicine, Hahnemann University School of Medicine,
Philadelphia, PA

- 1993 NCI Strategy Meeting on Breast Cancer in Young Women, National Institutes of Health,
Bethesda, MD
St. Georges Society, University of Maryland School of Medicine, Baltimore, MD
US-Japanese Joint Scientific Meeting on New Breast Cancer Therapies, Oakland, CA
Isaac Lewin Symposium, Baystate Medical Center, Springfield MA
Discussant, Adjuvant Breast Cancer Session, American Society of Clinical Oncology,
Orlando, FL
Educational Session, National Cancer Institute Phase I Meeting, Bethesda, MD
Working Group on the Pulmonary Complications Associated with Breast Cancer
Therapy, National Heart, Lung, and Blood Institute, National Institutes of Health,
Bethesda, MD
Shanghai Cancer Institute, Shanghai, Peoples Republic of China
Ethics and Politics in Clinical Trials, Johns Hopkins Medical Institutions, Baltimore, MD
NCI Workshop on Prognostic and Predictive Factors in Breast Cancer, Bethesda, MD
- 1994 Hematology/Oncology Grand Rounds, Wayne State University School of Medicine,
Detroit, MI
Clinical Oncology Program Grand Rounds, National Cancer Institute, Bethesda, MD
NCI Strategy Meeting on High Dose Chemotherapy for Breast Cancer, Bethesda, MD
11th Annual Advances in Cancer Treatment Research, Albert Einstein College of
Medicine, New York City, NY
Recent Advances in the Biology of Breast, Colon, and Lung Cancer, American Society of
Clinical Oncology, Dallas, TX
Discussant, Plenary Session, American Society of Clinical Oncology, Dallas, TX
Women's Health Seminar Series, Breast Cancer, National Institutes of Health,
Bethesda, MD
Chemotherapy Symposium, Berlex Oncology Foundation, Leesburg, VA
The State of Breast Cancer 1994: An Interactive Symposium, University of California at
San Francisco, San Francisco, CA
Grand Rounds, Washington County Hospital, Hagerstown, MD
Y-ME of the Cumberland Valley, Hagerstown, MD

- 1995 Department of Pharmacology and Toxicology, Robert C. Byrd Health Sciences Center of West Virginia University, Morgantown, WV
12th Annual International Breast Cancer Conference, Miami, FL
Controversy Session, American Association for Cancer Research, Toronto, Canada
Department of Pharmacology, Mayo Clinic, Rochester, MN
Susan G. Komen Foundation Congressional Breakfast, Washington, DC
Commonwealth of Massachusetts Course on Breast Cancer, Boston, MA
Law and Health Care Program, University of Maryland and Baltimore School of Law, Baltimore, MD
Discussant, Breast Cancer Session, American Society of Clinical Oncology, Los Angeles, CA
Topics in Clinical Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Gordon Research Conference on Mammary Gland Biology, New London, NH
The Endocrine Society's 51st Conference on Recent Progress in Hormone Research, Stevenson, WA
Eighteenth Thomas W. Green Memorial Lecture, East Tennessee State University James H. Quillen College of Medicine, Bristol, TN
Fifth International Congress on Hormones and Cancer, Quebec City, Canada
Cancer Medicine, Harvard Medical School, Boston, MA
Medical Oncology Board Review, George Washington University School of Medicine, Washington, DC
The First Annual Kimmel-Slavin Memorial Lecture, George Washington University School of Medicine, Washington, DC
Chemotherapy Symposium, Berlex Oncology Foundation, Leesburg, VA
Meet the Professor, American Society of Clinical Oncology Fall Educational Conference, Washington, DC
Grand Rounds, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Division of Hematology/Oncology, Washington Hospital Center, Washington, DC
18th Annual San Antonio Breast Cancer Symposium, San Antonio, TX
Department of Medicine, St. Joseph Hospital, Baltimore, MD
Dana-Farber Cancer Institute, Boston, MA
22nd Annual Symposium on the Diagnosis and Treatment of Neoplastic Disorders, Johns Hopkins
- 1996 Department of Embryology, Carnegie Institute of Washington, Baltimore, MD
Mayo Clinic Cancer Center, Rochester, MN
New Approaches to Cancer Therapy, The Johns Hopkins Oncology Center, Baltimore, MD
Topics in Clinical Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

University of Maryland Cancer Center, Baltimore, MD
Discussant, Breast Cancer Session, American Society of Clinical Oncology, Philadelphia, PA
Bowman Gray Comprehensive Cancer Center, Wake Forest University, Winston-Salem, N.C.
American College of Surgeons, San Francisco, CA
Session Chair, Gordon Conference on Cancer Chemotherapy, Oxford, UK
Chemotherapy Symposium, Berlex Oncology Foundation, Leesburg, VA
City of Hope National Medical Center, Duarte, CA
Upstate New York Cancer Research and Education Foundation, Syracuse, NY
Wendy and Emery Reeves International Breast Cancer Symposium, University of Texas Southwestern Medical Center, Dallas, TX 30th Anniversary Symposium, National Institute of Environmental Health Sciences, Research Triangle, NC
Meet the Professor, American Society of Clinical Oncology Fall Educational Conference, Phoenix, AZ
Maryland Cancer Control Symposium, Baltimore, MD
Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC
Department of Biochemistry, Johns Hopkins School of Hygiene and Public Health, Baltimore, MD

- 1997 Breast Cancer Think Tank 7, St. Lucia
4th Annual Breast Cancer Symposium of the New York Metropolitan Breast Cancer Group, New York City, NY
2nd Annual Multidisciplinary Symposium on Breast Disease, Amelia Island, FL
University of Colorado Cancer Center, Denver, CO
Cambridge Symposium, Genetic Approaches to Breast and Prostate Cancer, Lake Tahoe, CA
St. George's Society, University of Maryland Medical School, Baltimore, MD
Issues in the Treatment of Breast Cancer, Greater Baltimore Medical Center, Baltimore, MD
University of Chicago Cancer Center, Chicago, IL
Conjoint Clinic, Johns Hopkins University School of Medicine, Baltimore, MD
Breast Cancer Tumor Panel, American Society of Clinical Oncology, Denver, CO
Pittsburgh Cancer Institute, University of Pittsburgh Medical School, Pittsburgh, PA
International Cancer Alliance, Washington, DC
Perspectives in Breast Cancer, Emory University, Atlanta, GA
US Public Health Services Office on Women's Health Healthy Women 2000, Washington, DC
Chemotherapy Symposium, Berlex Oncology Foundation, Leesburg, VA
American College of Surgeons, Chicago, IL
Susan G. Komen Foundation Breast Cancer Symposium, Dallas, TX

Medical Oncology Board Review, George Washington University School of Medicine,
Washington, DC
Case Western Reserve University/Ireland Cancer Center, Cleveland, OH
Holy Cross Hospital, Silver Spring, MD
Department of Medicine and Cancer Center, University of California at San Francisco,
San Francisco, CA
American Society of Clinical Oncology Fall Education Conference, Orlando, FL
14th Annual American College of Physicians/Army Regional Meeting, Reston, VA
Fallston Hospital, Fallston, MD

- 1998 Breast Cancer Think Tank 8, Tobago
Session Co-Chair, 6th International Conference on Adjuvant Therapy of Primary Breast Cancer, St. Gallen, Switzerland
Controversy Session Chair, American Association for Cancer Research, New Orleans, LA
24th Annual Symposium on Diagnosis and Treatment of Neoplastic Diseases, Johns Hopkins Medical Institutions, Baltimore, MD
Breast Cancer Symposium, Inova Fairfax Hospital, Fairfax, VA
Discussant, Plenary Session, American Society of Clinical Oncology, Los Angeles, CA
Department of Pathology, Vanderbilt School of Medicine, Nashville, TN
Suburban Hospital, Bethesda, MD
Department of Medicine, Columbia-Presbyterian Medical Center, New York City, NY
Gordon Conference on Cancer, Newport, RI
Current Topics in Breast Cancer Research III: Cell Death in Breast Cancer, Cambridge, UK
Chemotherapy Symposium, Berlex Oncology Foundation, Leesburg, VA
2nd Annual Advances in Cancer Therapy, VCU/MCV, Richmond, VA
Kent and Queen Anne's Hospital, Chestertown, MD
Breast Cancer Awareness Month, The White House Washington, DC
Medical Oncology Board Review, George Washington University School of Medicine, Washington, DC
21st Annual San Antonio Breast Cancer Symposium, San Antonio, TX
- 1999 Breast Cancer Think Tank 9, St. Thomas, Virgin Islands
Joint Cancer Conference of the Florida Universities, Orlando, FL
Grand Rounds, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD
Congressionally Directed Medical Research Programs, Frederick, MD
Topics in Internal Medicine, Department of Medicine, Johns Hopkins, Baltimore, MD
American Society of Clinical Oncology, Atlanta, GA
1st Milan Breast Cancer Conference, Milan, Italy
Johns Hopkins Singapore, Singapore
Grand Rounds, Department of Surgery, Northwest Hospital, Baltimore, MD

6th Nottingham International Breast Cancer Conference, Nottingham, England
Seeking Excellence in Breast Cancer Care: Best Practices in Diagnosis and Treatment,
Johns Hopkins University School of Medicine, Baltimore, MD
First Annual Lynn Sage Breast Cancer Symposium, Robert H. Lurie Comprehensive
Cancer Center of Northwestern University, Chicago, IL
Chemotherapy Symposium, Berlex Oncology Foundation, Leesburg, VA
Cancer Medicine, Harvard Medical School, Boston, MA
41st Annual Meeting of the American Society of Therapeutic and Radiation Oncology,
San Antonio, TX
SERMs - Implication for Prevention and Treatment of Cancer, Philadelphia, PA
American Society of Clinical Oncology Fall Education Conference, San Francisco, CA
Genetics Program, University of Missouri, Columbia, MO
22nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX

- 2000 Sibley Hospital, Washington, DC
Franklin Square Hospital, Baltimore, MD
Molecular Biology of Breast Cancer, Lillehammer, Norway
Keystone Symposium in Advances in Human Breast and Prostate Cancer, Lake Tahoe,
NV
NIH Workshop on Selective Estrogen Receptor Modulators (SERMs), Bethesda, MD
Topics in Internal Medicine, Johns Hopkins University School of Medicine, Baltimore,
MD
National Breast Cancer Coalition Eighteenth Annual Advocacy Training Conference
2nd Milan Breast Cancer Conference, Milan, Italy
Australia - New Zealand Breast Cancer Trials Group, Queenstown, New Zealand
Suburban Hospital, Bethesda, MD
15th Annual Excalibur Round Table, American Cancer Society, Baltimore, MD
Susan G. Komen Breast Cancer Foundation National Symposium - Reaching for the
Cure..... Making a Difference, Washington, DC
WellStar Kennestone Hospital, Marietta, GA
WellStar Cobb Hospital, Marietta, GA
Hematology-Oncology Board Review, George Washington University School of
Medicine, Arlington, VA
Berlex Oncology Foundation Clinical Pharmacology of Anticancer Drugs, Leesburg, VA
42nd Annual Meeting of the American Society of Therapeutic and Radiation Oncology,
Boston, MA
National Institutes of Health Consensus Development Conference on Adjuvant Therapy
of Breast Cancer, Bethesda, MD
Seeking Excellence in Breast Cancer Care, Johns Hopkins University School of Nursing
and School of Medicine, Baltimore, MD
- 2001 Breast Cancer Think Tank 11, Punta Cana, Dominican Republic Potential Clinical
Applications for GnRH Agonists, National Institutes of Health, Bethesda, MD

7th International Conference on Adjuvant Therapy of Primary Breast Cancer, St. Gallen, Switzerland

8th Annual Miami Breast Cancer Conference, Miami, FL

Central Pennsylvania Oncology Group, Harrisburg, PA

Mary E. Humphreys Biology Lecture, Mary Baldwin College, Staunton, VA

Department of Medicine Grand Rounds, Johns Hopkins Bayview, Baltimore, MD

Discussant, American Society of Clinical Oncology, San Francisco, CA

Anne Arundel Medical Center, Annapolis, MD

Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

Women's Malignancy Group, MD Anderson Cancer Center, Houston, TX

3rd Milan Breast Conference, Milan, Italy

Gordon Conference on Polyamines, New London, CT

Australian Society for Breast Diseases, Surfers Paradise, Australia (by video conference)

White House/Komen Breast Cancer Summit, Washington, DC

3rd Annual Lynn Sage Breast Cancer Symposium, Northwestern University, Chicago, IL

Hematology-Oncology Board Review, George Washington University School of Medicine, Arlington, VA

Berlex Oncology Foundation Clinical Pharmacology of Anticancer Drugs, Leesburg, VA

Tumor Board, Greater Baltimore Medical Center, Baltimore, MD

Hematology Grand Rounds, Johns Hopkins, Baltimore, MD

William L. McGuire Memorial Lecture, 24th Annual San Antonio Breast Cancer Symposium, San Antonio, TX

- 2002 Breast Cancer Symposium Think Tank 12, St. Maarten, The Netherlands Antilles
Grand Rounds Department of Medicine, Johns Hopkins University, Baltimore, MD
Current Trends in Breast Cancer, Philadelphia, PA
3rd European Breast Cancer Conference, Barcelona, Spain
The Third North American Symposium on Skeletal Complications of Malignancy,
National Institutes of Health, Bethesda, MD
Educational Symposium, American Society for Clinical Oncology, Orlando, FL
4th Milan Breast Cancer Conference, Milan, Italy
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer. Cambridge, MA
Breast Cancer: Current Controversies and New Horizons, Dana Farber Cancer Institute, Boston, MA
Center for Cancer Research Grand Rounds, National Cancer Institute, Bethesda, MD
2nd Annual Karmanos Cancer Institute Breast Cancer Symposium, Detroit, MI
Era of Hope, Department of Defense Breast Cancer Research Program, Orlando, FL
Fox Chase Cancer Center, Philadelphia, PA
IX Congresso Nacional de Oncologia, Lisbon, Portugal

- 2003 NCI – Hopkins Workshop on Clinical Translation of Gene Re-expression in Cancer, Baltimore, MD

Breast Cancer Think Tank 13, Aruba
20th Annual Miami Breast Cancer Conference, Miami, FL
8th International Conference on Primary Therapy of Early Breast Cancer, St. Gallen, Switzerland
American Society for Breast Disease, Dallas, TX
Upper Chesapeake Medical Center, Fallston, MD
American Society of Clinical Oncology, Chicago, IL
Gordon Conference on Cancer Chemotherapy, Oxford, UK
National Cancer Institute Workshop on Ductal Lavage, Bethesda, MD
9th Annual Perspectives in Breast Cancer, Boston, MA
Cancer Education Consortium Clinical Pharmacology of Anticancer Agents, Leesburg, VA
Indiana University Cancer Center, Indianapolis, IN
4th Annual Hampton Roads Fall Cancer Conference, Portsmouth, VA
Friends of Cancer Research, Woodrow Wilson International Center for Scholars, Washington, DC
AstraZeneca Breast Cancer Symposium, Waltham, MA

2004 Breast Cancer Think Tank 14, St Kitts
Translational Conference, Johns Hopkins Oncology Center, Baltimore, MD
Current Trends in Breast Cancer: Updates from the 2003 San Antonio Breast Cancer Symposium, Washington, DC
Breast Cancer—Bench to Bedside, Loyola University, Chicago, IL
Massachusetts General Hospital, Boston, MA
4th European Breast Cancer Conference, Hamburg, Germany
American Association for Cancer Research, Orlando, FL
The Philip A. Tumulty Topics in Clinical Medicine at Johns Hopkins, Baltimore, MD
Medical Grand Rounds, University of Florida—Shands Medical School, Gainesville, FL
Henry Lemon Memorial Lecture, University of Nebraska—Eppley Cancer Center, Omaha, NE
Discussant, Best of Oncology Symposium, American Society of Clinical Oncology, New Orleans, LA
6th Milan Breast Cancer Symposium, Milan, Italy
Gordon Conference on Molecular Therapeutics of Cancer, New London, NH
7th Annual Mission Conference of the Susan G. Komen Breast Cancer Foundation, Washington, DC
George Washington University Hematology-Oncology Board Review Course, Alexandria, VA
Cancer Education Consortium Clinical Pharmacology of Anticancer Agents, Leesburg, VA
6th Lynn Sage Breast Cancer Symposium of Northwestern University, Chicago, IL
Alta Bates Summit Medical Center, Berkeley, CA
Association of Northern California Oncologists, San Francisco, CA

4th American Association for Cancer Research Prevention Meeting, Seattle, WA
Project LEAD, National Breast Cancer Coalition, Washington, DC
Mayo Clinic Oncology Society, Rochester, MN
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic,
Rochester, MN
Career Day, Baltimore Polytechnic Institute, Baltimore, MD
2nd Breast Cancer Inter-SPORE Meeting, Chapel Hill, NC
27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX

- 2005 Greenebaum Cancer Center, University of Maryland Medical School, Baltimore, MD
Breast Cancer Think Tank 15, Curacao
22nd Miami Breast Cancer Symposium, Miami, FL
Lorne Cancer Conference, Phillip Island, Australia
Delaware Oncology Society, Wilmington, DE
New Strategies in Breast Cancer Conference, Philadelphia, PA
Educational Symposium, American Society of Clinical Oncology, Orlando, FL
Highlights of the Day Symposium, American Society of Clinical Oncology, Orlando, FL
National Breast Cancer Coalition Fund Annual Advocacy Conference, Washington, DC
Third International Symposium on the Molecular Biology of Breast Cancer, Molde,
Norway
Breast Cancer: Current Controversies and New Horizons, Harvard Medical School,
Boston, MA
New England Journal of Medicine Clinical Pathologic Conference, Harvard Medical
School, Boston, MA
Hematology-Oncology Board Review, George Washington University Medical Center,
Washington, DC
Frances Bull Lecture, University of Michigan, Ann Arbor, MI
University of Minnesota Cancer Center, Minneapolis, MN
50th Anniversary Avon Foundation Symposium, New York City, NY
Cancer Education Consortium Clinical Pharmacology of Anticancer Agents, Leesburg,
VA
100 Women Professors Symposium, Johns Hopkins, Baltimore, MD
Working Group on Translational Epigenetics in Cancer, National Cancer Institute,
Bethesda, MD
- 2006 Mayo Clinic, Rochester, MD
Helen Padykula Lecture, Wellesley College, Wellesley, MA
Lynne Abraham Symposium, Susan G. Komen Foundation, New York City, NY
Third Current Concepts in the Multidisciplinary Management of Breast Cancer, Johns
Hopkins, Baltimore, DC
Forum on Breast Cancer Prevention. American Association of Cancer Research,
Washington, DC
Vth Santiago Breast Cancer Symposium, Santiago, Chile

8th Milan Breast Cancer Symposium, Milan, Italy
International Union Against Cancer (UICC) World Cancer Congress, Washington, DC
8th Lynn Sage Breast Cancer Symposium, Chicago, IL
Hematology-Oncology Board Review, George Washington University Medical Center,
Washington, DC
Cancer Education Consortium Clinical Pharmacology of Anti-Cancer Agents, Leesburg,
VA
44th Meeting of the Japan Society of Clinical Oncology, Tokyo, Japan
National Comprehensive Cancer Network Adjuvant Therapy in Breast Cancer
Symposium, Baltimore, MD
Women's Board, Johns Hopkins Hospital, Baltimore, MD
National Cancer Institute-Ft. Detrick Distinguished Scientist Seminar, Frederick, MD
Science Lecture Series 2006-7 Radcliffe Institute for Advanced Study, Cambridge, MA

- 2007 Johns Hopkins Workshop on Clinical Targeting of Epigenetic Changes in Cancer Treatment, Phoenix, Arizona
24th Annual Miami Breast Cancer Conference, Miami, FL
6th Annual Mid-Atlantic Oncology Update, St Agnes Hospital, Baltimore, MD
10th International Conference on Primary Therapy of Early Breast Cancer, St. Gallen,
Switzerland
Breast Cancer Think Tank 17, Playa del Carmen, Mexico
Annual Advances in Basic Science Symposium, Northwestern University Cancer Center,
Chicago, IL
American Society of Clinical Oncology Education Symposium, Chicago, IL
10th Komen Mission Conference, Washington, DC
St Joseph's Hospital, Baltimore, MD
Australia-New Zealand Breast Cancer Clinical Trials Annual Meeting, Alice Springs,
Australia
National Cancer Advisory Board, Bethesda, MD
Hematology-Oncology Board Review, George Washington University Medical Center,
Washington, DC
CR-UK Cambridge Research Institute Plenary Lecture, 3rd National Cancer Research
Institute Cancer Conference, Birmingham, UK
President's Cancer Panel, San Diego, CA
Scientific Symposium, Breast Cancer Research Foundation, New York City, NY
Florida Oncology Society, Orlando, FL
Collaborative Summit on Breast Cancer Research, Foundation for the NIH, Lansdowne,
VA
American Association of Cancer Research Prevention Symposium, Philadelphia, PA
- 2008 7th Rosalind E. Franklin Award for Women in Science, National Cancer Institute,
Bethesda, MD
Breast Cancer Think Tank 18, Waikaloa, HI

- Cancer Institute of New Jersey, New Brunswick, NJ
5th Early Detection Research Network Scientific Workshop, National Cancer Institute, Bethesda, MD
Vanderbilt-Ingram Comprehensive Cancer Center, Nashville, TN
11th American Association for Cancer Research-Women in Cancer Research Charlotte Friend Award, San Diego, CA
14th Annual Educational Symposium, Susan G. Komen for the Cure Maryland, Baltimore, MD
4th Current Concepts in the Multidisciplinary Management of Breast Cancer, Johns Hopkins University, Baltimore, MD
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA
Best of ASCO, Boston, MA
Annual Meeting of the American Association for Clinical Chemistry, Washington, DC
Seventh International Congress on the Future of Breast Cancer, Kauai, HI
Nuclear Hormone Receptors, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
Hematology-Oncology Board Review, George Washington University, Washington, DC
Fourth Annual Oncology Congress, San Francisco, CA
Oberstar Lecture, George Washington University, Washington, DC
- 2009 Breast Cancer Think Tank 19, Costa Rica
Bernard Fisher Lecture, University of Pittsburgh, Pittsburgh PA
11th International Congress Oncology Conference on Primary Therapy of Early Breast Cancer, Saint Gallen, Switzerland
Grand Rounds, MD Anderson Cancer Center – Houston TX
Women Leading the Way, MD Anderson Cancer Center, Houston, TX
Jean Sindab Lecture, Emory Winship Cancer Institute, Atlanta, GA
Oncology Grand Rounds, Ohio State University, Columbus, OH
16th Annual Pennsylvania Bar Association Women in the Profession, Pittsburgh, PA
American Society of Clinical Oncology Educational Symposium, Orlando, Fl
24th Annual Aspen Cancer Conference, Aspen, CO
Harvard Breast Cancer Conference, Boston, MA
Medical Grand Rounds, UPMC Shadyside Hospital, Pittsburgh, PA
University of Pittsburgh Postdoctoral Association Data and Dine Lecture, Pittsburgh, PA
Women's Studies and the Provost's Advisory Committee on Women's Concerns New Faculty Lecture, University of Pittsburgh, Pittsburgh, PA
Pancreasfest 2009, University of Pittsburgh, Pittsburgh, PA
AACR Advances in Breast Cancer Research, San Diego, CA
Cincinnati Cancer Symposium, Jensen Symposium on Nuclear Receptors, Cincinnati, Ohio
Translating Scientific Advances into Clinical Care Cancer, Lineberger Comprehensive Cancer Center, Chapel Hill, NC
New Options in Breast Cancer Treatment, UPMC Cancer Centers, Johnstown, PA

- 2010 University of Pittsburgh Winter Academy, Naples, FL
Achievement Rewards for College Scientists, Pittsburgh, PA
Medical Grand Rounds, UPMC Montefiore University Hospital, Pittsburgh, PA
Katz Lecture, Magee Womens Hospital of Pittsburgh, Pittsburgh, PA
NYU Cancer Institute Seminar Series, New York, NY
The Regional Cancer Center, Erie, PA
Lesses Visiting Professor, Medical Grand Rounds, Beth Israel Deaconess Medical Center, Boston, MA
Hematology-Oncology Grand Rounds, Beth Israel Deaconess Medical Center, Boston, MA
University of Maryland Marlene and Stewart Greenebaum Cancer Center, Hormone Responsive Cancer Program Retreat, Baltimore, MD
Lois O'Grady Breast Cancer Lecture, University of California Davis Cancer Center, Sacramento, CA
11th Annual Advances in Oncology, University of California Davis Cancer Center, Sacramento, CA
American Society of Clinical Oncology Breast Cancer Symposium - Gianni Bonadonna Award, Washington, DC
Advances in Oncology, Keynote speaker, UPMC Beacon Hospital, Ireland
Oncology Grand Rounds, Thomas Jefferson University Kimmel Cancer Center, Philadelphia, PA
- 2011 Dept of Environmental & Occupational Health, University of Pittsburgh, Pittsburgh, PA
Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA
Breast Cancer Program Retreat, UCSF Cancer Center, San Francisco, CA
Lineberger Cancer Center, UNC Chapel Hill, Chapel Hill, NC
XI Michelangelo Foundation Seminar, Milan Italy
Georgetown University, Undergraduate Research Conference Keynote Speaker, Washington, DC
City of Hope Cancer Center Grand Rounds, Duarte, CA
Cleveland Clinic Grand Rounds, Taussig Cancer Center, Cleveland, Ohio
McArdle Laboratory Seminar, University of Wisconsin, Madison, WI
13th Milan Breast Cancer Conference, Milan, Italy
Annual Meeting, American Society of Clinical Oncology, Chicago, IL
International Cancer Conference, Trinity Medical School, Dublin, Ireland
Fifth Annual Ri.MED Scientific Symposium, Palermo, Italy
Medical Oncology Board Review, George Washington University, Washington, DC
Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA
Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pgh, PA
San Antonio Breast Cancer Symposium, San Antonio, TX

- 2012 Breast Cancer Think Tank 22, Mexico
Siteman Cancer Center at Washington University, Saint Louis, MO
Miami Breast Cancer Conference, Miami, FL
University of Pittsburgh Department of Pathology, Pittsburgh, PA
American Society of Preventive Oncology, Washington, DC
Tsinghua University, Beijing, China
University of Pittsburgh, Chancellors Inaugural Lecture - Hillman Professor of Oncology,
Pittsburgh, PA
University of Chicago Cancer Biology Seminar Series, Chicago, IL
Johns Hopkins University School of Medicine, Baltimore, MD
American Society of Clinical Oncology, Chicago, IL
34th Annual Scientific Meeting, Australia-New Zealand Breast Cancer Trials Group,
Hobart, Australia
Medical Oncology Board Review, George Washington University, Washington, DC
University of Texas Southwestern, Pamela Hearn Isom Lecture, Medicine Grand
Rounds, Dallas Texas
Potamkin Lecture, PA Breast Cancer Coalition Conference, Harrisburg, PA
Northwestern University Feinberg School of Medicine's 16th Annual Department of
Pathology Joseph C. Calandra Lecture, Chicago, IL
The Shanghai Breast Cancer Symposium, Shanghai, China
- 2013 Bay City Capital Scientific Advisory Board Meeting
13th International Congress Oncology Conference on Primary Therapy of Early
Breast Cancer, St. Gallen, Switzerland
Annual Meeting, American Association of Cancer Research, Washington, DC
Case Western Reserve Comprehensive Cancer Center, Cleveland, Ohio
Medical Oncology Board Review, George Washington University, Washington, DC
The Hong Kong University of Science and Technology, Tetralateral Symposium,
Hong Kong
PA Cancer Planning Summit, Pittsburgh, PA
Breast Cancer Symposium, San Francisco, CA
Cancer Caucus, House of Representatives, Harrisburg, PA
Science 2013, Pittsburgh, PA
Global Breast Cancer Conference, Seoul, South Korea
- 2014 Annual Meeting, American Association for Cancer Research, San Diego, CA
American Society of Clinical Oncology, Chicago, IL
German Cancer Research Center (DKFZ), Heidelberg, Germany
Medical Oncology Board Review, George Washington University, Washington, DC
National Cancer Advisory Board, Bethesda, MD
International Oncology Symposium, Astana, Kazakhstan
University of Chicago Simon M. Shubitz Lecture, Chicago, IL
Congressional Briefing, Alliance for Health Reform, Washington, DC

San Antonio Breast Cancer Conference, San Antonio, TX

- 2015 14th St. Gallen International Breast Cancer Conference, Primary Therapy of Early Breast Cancer, Vienna, Austria
Pediatric Hematology/Oncology Pediatric Hematology/Oncology BMT & CT Conference, Childrens Hospital of Pittsburgh, Pittsburgh, PA
University of Pittsburgh, Winter Academy, Palm Beach, Florida
The Wistar Institute, Distinguished Lecture, Philadelphia, PA
Annual Meeting, American Association for Cancer Research, Philadelphia, PA
Inaugural Lecture as Distinguished Professor of Medicine, University of Pittsburgh, Pittsburgh PA
Stephen D Williams, MD Lectureship, Indiana University Simon Cancer Center, Indianapolis, IN
Medical Oncology Board Review, George Washington University, Washington, DC
ASCO 2015 Breast Cancer Symposium, San Francisco, CA
Taipei Medical University, Taipei, Taiwan
Eighth Annual Robert B. Dickson Memorial Lectureship, Georgetown University Lombardi Cancer Center, Washington DC
First Gabriel Hortobagyi Lecture, MD Anderson Cancer Center, Houston, TX

3. Other research related activities

PATENTS GRANTED:

US Patent 7,858,317 B2 Aberrantly methylated genes as markers of breast malignancy (Sukumar S, Evron E, Dooley WC, Sacchi N, Davidson N, Fackler MJ). Issued December 28, 2010

EDITORIAL BOARDS:

1993-1995, 2006-9	Journal of Clinical Oncology
1995-2005	Cancer Research
1995-2009	The Breast Journal
1996-2011	The Breast
1997-2005	American Journal of Medicine
1999-2005	Clinical Cancer Research
2007-2014	Hem/Onc Today
2008-present	Oncology
2008-present	Cancer Prevention Research
2012-present	Journal of the National Cancer Institute
2012-present	Breast Cancer Research and Treatment

STUDY SECTION MEMBERSHIPS:

1988	Member, Ad Hoc Technical Review Section, National Cancer Institute, Bethesda, MD
1990, 1991, 1992	Ad Hoc Member, Reproductive Endocrinology Study Section, National Institutes of Health, Bethesda, MD
1992-1993	Member, Awards Committee, Susan G. Komen Foundation, Dallas, TX
1993-1997	Member, Reproductive Endocrinology Study Section, National Institutes of Health, Bethesda, MD
1994	Member, Walt Disney – American Cancer Society Breast Cancer Professorship Selection Committee, Atlanta, GA
1997-1998	Co-Chair, Progress Review Group for Breast Cancer Research, National Cancer Institute, Bethesda, MD
1996-1998	Chair, Pre-clinical and Clinical Studies Study Section, California Breast Cancer Research Program, San Francisco, CA
1999-present	Medical Advisory Board, Breast Cancer Research Foundation, New York City, NY
2001	Member, Breast and Prostate SPORE Review Group, National Cancer Institute
2002	Co-chair, Breast Cancer SPORE Review Group, National Cancer Institute
2003-2008	Vice-Chair, National Cancer Institute Breast Cancer Intergroup Correlative Science Committee
2002-2005	Member, Charles Kettering Prize Selection Committee, General Motors Cancer Research Foundation, Chair, 2005
2003	Chair, Innovator Award Review Committee, Department of Defense Breast Cancer Program
2005	Member, Lung and Bladder Cancer SPORE Review Group, National Cancer Institute
2005-2006	Ad hoc member, Kimmel Scholars Award Committee
2006-present	Member, Kimmel Scholars Award Committee
2006-2010	Member, Subcommittee A – Cancer Centers, National Cancer Institute
2008	Co-chair, Lung Cancer and Lymphoma SPORE Review Group, National Cancer Institute
2008-present	Member, Scientific Advisory Board, V Foundation for Cancer Research
2008	Chair, Therapeutic Targets I Review Committee, Susan G Komen for the Cure
2012-present	Member, Damon Runyon Cancer Research Foundation Clinical Investigator Award Committee
2012-2013	Chair of the Cancer Program Review, Helmholtz Senate Commission, Helmholtz Association of German Research Centers, Berlin, Germany
2014	Member, Scientific Advisory Committee, Breakthrough Breast Cancer, London, UK
2014-	Chair, CTAC SPORE Program Evaluation Working Group, NCI
2015	Chair, Stand Up To Cancer Canada-Canadian Breast Cancer Foundation Breast Cancer Dream Review Team Committee

EXTRA-MURAL GRANT REVIEWING

Ad hoc grant reviewer for: National Institutes of Health, American Cancer Society, Veterans Administration, Manitoba (Canada) Health Council, Health Research Council of New Zealand, National Cancer Institute - Canada, Medical Research Council - Canada, Department of Defense Breast Cancer Program, many others

ADVISORY BOARD MEMBERSHIPS:

2000-present	Member, External Advisory Board, Vanderbilt-Ingram Cancer Center, Nashville, TN
2001-2006	Member, External Advisory Board, Fox Chase Cancer Center, Philadelphia, PA
2001-2011	Member, External Advisory Board, Bay Area UCSF Breast Cancer SPORE, San Francisco, SF
2003-present	Member, External Advisory Board, Karmanos Cancer Center, Detroit, MI
2003-2008	Member, External Advisory Board, Indiana University Cancer Center, Indianapolis, IN
2005-present	Member, External Advisory Board, University of Maryland Cancer Center, Baltimore, MD
2008-present	Member, Board of Scientific Consultants, Memorial Sloan Kettering Cancer Center, New York City, NY
2008-present	Member, External Advisory Board, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, Chair 2014-
2009-present	Member, External Advisory Board, MD Anderson Cancer Center, Houston, TX Chair 2014-
2010-present	Member, External Advisory Board, University of Michigan Comprehensive Cancer Center
2010-present	Member, External Advisory Board, Washington University Siteman Cancer Center, St. Louis, MO
2010-present	Member, External Advisory Board Breast Cancer SPORE, Mayo Clinic, Rochester, MN
2010-present	Member, External Advisory Board, Institut National du Cancer, Paris, France
2012-present	Member, Scientific Advisory Board, CTSA, Case Western Reserve University School of Medicine, Cleveland, Ohio
2012-present	Member, Scientific Advisory Board, Cologne Center for Integrated Oncology, Cologne, Germany
2012-present	Member, External Advisory Board, Fred Hutchinson Cancer Research Center University of Washington Cancer Consortium, Seattle, Washington
2013-present	Member, External Advisory Board, Baylor College of Medicine Breast Cancer SPORE
2014-present	Member, External Advisory Board, University of Chicago Comprehensive Cancer Center, Chicago, IL
2014-2015	Member, Scientific Advisory Board, A. Alfred Taubman Medical Research Institute, University of Michigan, Ann Arbor, MI

LIST OF CURRENT RESEARCH INTERESTS:

Cancer biology and treatment, especially breast cancer

SERVICE

1. UNIVERSITY AND MEDICAL SCHOOL:

Committees - Johns Hopkins

- | | |
|-----------|---|
| 1987 | Co-Director, Oncology Multidisciplinary Conference |
| 1987-1997 | Member, Oncology Fellowship Selection Committee |
| 1993-1995 | Department Representative, Medical School Council |
| 1999-2003 | Departmental Appointments and Promotions Committee |
| 2000-2005 | Member, School of Medicine Professorial Promotion Committee |
| 2001-2009 | Member, MD-PhD Admissions Committee |
| 2003-2005 | Member, Search Committee for Director of Biophysics and Biophysical Chemistry |

Committees – University of Pittsburgh, University of Pittsburgh Physicians (UPP), UPMC

- | | |
|--------------|---|
| 2009-present | Member, Chair Management Committee |
| 2009-present | Member, UPP Clinical Chairs Committee |
| 2009-present | Member, Breast Cancer Steering Committee |
| 2009-present | Member, Clinical Research Oversight Committee |
| 2009-2012 | Member, ReSet Steering Committee |
| 2009-present | Member, Adolescent and Young Adult Cancer Committee |
| 2010-2011 | Member, Search Committee for Department of Medicine Chairman |
| 2011-2012 | Member, Search Committee for the Institute of Personalized Medicine |
| 2012-present | Member, UPMC Presbyterian Shadyside Hillman Cancer Committee |
| 2012-present | Member, School of Medicine Financial Oversight Committee |
| 2014-present | Member, Internal Advisory Board Gynecologic SPORE |
| 2015-present | Member, Internal Advisory Board for the Center for Causal Discovery |
| 2015-present | Member, Internal Advisory Board of the Center for Medical Counter Measures Against Radiation (CMCR) |

2. EXTERNAL ORGANIZATIONS:

- | | |
|-----------|--|
| 1993-1995 | Member, Medical Advisory Committee, Maryland Cancer Consortium |
| 1994-1996 | Executive Committee, American Cancer Society – Maryland Division
Chair, Research Committee |
| 1995-1998 | Member, Medical Knowledge Self Assessment Program 11-Oncology, American College of Physicians |
| 1999-2000 | Planning Committee, National Institutes of Health Consensus Development Conference on Adjuvant Therapy for Breast Cancer, Bethesda, MD |
| 1998-2001 | Data Monitoring Committee, Southwest Oncology Group |
| 1999-2006 | Data Monitoring Committee, RUTH Trial, Lilly |

2000-2006	Data Monitoring Committee, Breast Cancer International Research Group (BCIRG)
2003, 2005, 2007, 2009, 2011, 2013, 2015	Member, St. Gallen Consensus Panel, St. Gallen, Switzerland
2006-2011	Member, Data and Safety Monitoring Committee, TEACH Trial, Glaxo Smith Kline
2009-2012	NMR Center Advisory Committee, Carnegie Mellon University
2010-present	Co-Chair, Breast Cancer Steering Committee, National Cancer Institute
2011-present	Member, Clinical Trials and Translational Research Advisory Committee (CTAC), National Cancer Institute, Chair 2015-present
2013-present	Board of Trustees, Phipps Conservatory, Pittsburgh, PA
2015-	Member, Search Committee for the Scientific Director (SD), Center for Cancer Research (CCR), National Cancer Institute
2015-	Member, Breast Cancer Now's Science Strategy Committee